k yevkhtm form ktable contents united states securities exchange commission washington dc annual report pursuant section securities exchange act fiscal year ended december oo transition report pursuant section securities exchange act transition period commission file number scheringplough corporation exact name registrant specified charter new jersey state jurisdiction irs employer incorporation organization identification galloping hill road kenilworth nj address principal executive offices zip code registrants telephone number including area code securities registered pursuant section b act title class name exchange registered common shares par value new york stock exchange mandatory convertible preferred stock new york stock exchange preferred share purchase rights new york stock exchange time filing rights traded separately common shares securities registered pursuant section g act none indicate check mark registrant wellknown seasoned issuer defined rule securities act yes indicate check mark registrant required file reports pursuant section section act yes indicate check mark whether registrant filed reports required filed section securities exchange act preceding months shorter period registrant required file reports subject filing requirements past days yes indicate check mark disclosure delinquent filers pursuant item regulation sk chapter contained herein contained best registrants knowledge definitive proxy information statements incorporated reference part iii amendment indicate check mark whether registrant large accelerated filer accelerated filer nonaccelerated filer smaller reporting company see definitions large accelerated filer accelerated filer smaller reporting company rule b exchange act check one nonaccelerated filer large accelerated filer accelerated filer check smaller reporting company smaller reporting company indicate check mark whether registrant shell company defined rule b act yes state aggregate market value voting nonvoting common equity held nonaffiliates computed reference price common equity last sold average bid asked price common equity june last business day registrants recently completed second fiscal quarter common shares outstanding january part documents incorporated referenc e incorporated scheringplough corporation proxy statement part iii annual meeting shareholders may table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report internal control financial reporting part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures exd stock incentive plan exeviii employment agreement brent saunders exj severance benefit plan ex computation ratio earnings fixed charges ex subsidiaries ex consent independent registered public accounting firm ex independent auditor 's consent ex power attorney ex certification ex certification ex certification ex certification table contents part item business overview business scheringplough refers scheringplough corporation subsidiaries except otherwise indicated context schering corporation predecessor company incorporated new york new jersey trademarks indicated capital letters k property licensed promoted distributed scheringplough corporation subsidiaries related companies scheringplough innovationdriven sciencecentered global health care company biopharmaceutical research collaborations partners scheringplough creates therapies help save improve lives around world scheringplough applies researchanddevelopment platform human prescription animal health consumer products scheringploughs vision earn trust every day doctors patients customers shareholders employees stakeholders scheringplough based kenilworth nj web site wwwscheringploughcom april board directors recruited fred hassan join scheringplough new chairman board chief executive officer support board soon arrived hassan installed new senior executive management team initiated strategic plan goal stabilizing repairing turning around scheringplough order build longterm shareholder value strategic plan action agenda six eightyear fivephase plan four years since hassan new management team arrived scheringplough made substantial progress fourth phase action agenda build base scheringplough grew broadened base marketed products expanded late stage research development project pipeline closed transformative acquisition organon biosciences nv obs akzo nobel acquiring obs scheringplough gained organon human prescription business intervet animal health business additional strength key scheringplough current environment pharmaceutical industry continues subject evermore critical scrutiny challenges arise presenting scientific data objective manner scheringplough believes new scientific data best presented discussed appropriate scientific medical forums explained detail later k early scheringplough encountered challenge results merckscheringplough pharmaceuticals merckscheringplough cholesterol joint venture clinical trial called enhance joint venture products zetia vytorin became subject much media scrutiny prior presentation trial results appropriate medical forums results scheduled presented american college cardiology meeting march trial failed show statistically significant difference treatment groups primary endpoint mean change intimamedia thickness measured three sites carotid arteries right left common carotid internal carotid carotid bulb patients heterozygous familial hypercholesterolemia trial demonstrate vytorins effectiveness compared simvastatin lowering ldl cholesterol often known bad cholesterol medical experts health advisory groups long recognized high ldl cholesterol significant cardiovascular risk factor recommended increasingly aggressive treatment high cholesterol certain patients lowering ldl cholesterol along healthy diet lifestyle changes remains cornerstone lipid treatment patients risk heart disease clinical studies demonstrated vytorin lowers patients ldl cholesterol rosuvastatin atorvastatin simvastatin doses studied able get patients ldl cholesterol goals defined atp iii early tell impact joint ventures enhance trial results joint ventures cholesterol business scheringploughs diversified group products geographic areas well highly experienced executive team gives scheringplough additional strength helpful weathering situation table contents segment information scheringplough three reportable segments human prescription pharmaceuticals animal health consumer health care segment sales lossprofit data follow consistent scheringploughs current management reporting structure human prescription pharmaceuticals human prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products within human prescription pharmaceutical segment scheringplough broad range research projects marketed products six therapeutic areas cardiovascular central nervous system immunology infectious disease oncology respiratory womens health human prescription pharmaceuticals segment also includes nobilon human vaccine development unit diosynth thirdparty manufacturing unit marketed products include following cardiovascular disease vytorin cholesterollowering tablet combining dual action zetia merck co incs statin zocor simvastatin zetia novel cholesterolabsorption inhibitor discovered scheringplough scientists use monotherapy combination either statins fenofibrate lower cholesterol integrilin injection platelet receptor gp iibiiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention united states well prevention early myocardial infarction patients acute coronary syndrome countries orgaran nonheparin antithrombotic central nervous system remeron antidepressant esmeronzemuron muscle relaxant used surgical procedures subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone marketed scheringplough certain countries outside united states treatment opiate addiction norcuron muscle relaxant immunology infectious disease remicade antitnf antibody marketed scheringplough outside united states japan certain asian markets treatment inflammatory diseases rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis pegintron powder injection pegylated interferon product chronic hepatitis c avelox marketed us broadspectrum fluoroquinolone antibiotic certain respiratory skin infections noxafil oral suspension prophylaxis prevention invasive fungal infections highrisk patients treatment oropharyngeal candidiasis also approved treatment invasive fungal infections markets outside us oncology temodartemodal capsules certain types brain tumors including newly diagnosed glioblastoma multiforme caelyx longcirculating pegylated liposomal formulation cancer drug doxorubicin marketed scheringplough outside united states treatment certain ovarian cancers kaposis sarcoma metastatic breast cancer intron injection marketed chronic hepatitis b c numerous anticancer indications worldwide including adjuvant therapy malignant melanoma respiratory nasonex oncedaily nasalinhaled steroid nasal allergy symptoms including congestion treatment nasal polyps patients years age older clarinexaerius nonsedating antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist marketed scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduced bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil hfa albuterol inhalation solution relief bronchospasm patients years older womens health follistimpuregon fertility treatment nuvaring vaginal contraceptive ring livial menopausal therapy marvelondesogen lowdose combined oral contraceptive mercilon lowdose combined oral contraceptive implanon singlerod subdermal contraceptive implant table contents animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal marketed products segment include livestock products nuflor bovine swine antibiotic bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory trimerit data management tool cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease mpac swine pneumonia vaccine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines poultry companion animal products galaxyquantumprocyoneclipseintratrac vaccine line dogs cats nobivaccontinuum vaccine lines flexible dog cat vaccination otomaxmometamax canine otic ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals scaliborexspot dog collarspot protecting bites fleas ticks mosquitoes sandflies homeagain proactive us pet recovery network zubrin antiinflammatoryanalgesic dogs aquaculture products norvaxminova vaccines bacterial viral disease fish slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish consumer health care consumer health care segment develops manufactures markets otc foot care sun care products principal products segment include overthecounter otc products claritin nonsedating antihistamines miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure drixoral cold allergy allergy sinus flu nasal decongestant tablets afrin nasal decongestant spray correctol laxative tablets foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils lipprotection products sunless tanning products solarcaine sunburn relief products net sales segment yea r ended decem b er dollars millions human prescription pharmaceuticals animal health consumer health care consolidated net sales table contents lossprofit segment year e nded ecem b er dollars millions human prescription pharmaceuticals animal health consumer health care corporate including net interest income million million million respectively consolidated lossprofit tax cumulative effect change accounting principle human prescription pharmaceuticals segments loss includes billion purchase accounting items including acquired inprocess research development billion animal health segments loss includes million purchase accounting items including acquired inprocess research development million scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting see note equity income item financial statements supplementary data additional information equity income merckscheringplough joint venture included human prescription pharmaceuticals segment corporate includes interest income expense foreign exchange gains losses currency option gains headquarters expenses special acquisition related charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies item financial statements supplementary data corporate includes special acquisition related charges million comprised million integration related costs obs acquisition million severance charges part integration activities estimated charges relate reportable segments follows human prescription pharmaceuticals million animal health million corporate million corporate includes special charges million primarily related changes scheringploughs manufacturing operations us puerto rico announced june related human prescription pharmaceuticals segment included cost sales charges approximately million manufacturing streamlining actions primarily related human prescription pharmaceuticals segment corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve approximately million representing scheringploughs current estimate resolve massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters item financial statements supplementary data estimated charges relate reportable segments follows human prescription pharmaceuticals million consumer health care million animal health million corporate million see note special acquisition related charges manufacturing streamlining item financial statements supplementary data additional information table contents information merckscheringplough joint venture may scheringplough merck co inc merck entered two separate sets agreements jointly develop manage certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy marketed zetia us asia ezetrol europe ii coadministration various approved statin drugs iii fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched several international markets scheringplough utilizes equity method accounting recording share activity merckscheringplough joint venture see note equity income item financial statements supplemental data additional information regarding profits costs sharing accounting provided agreements allergyasthma agreements provide joint development marketing companies oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis new drug application filing combination tablet accepted us food drug administration fda standard review scheringplough announced agreed merck commence development singletablet combination ezetimibe atorvastatin treatment elevated cholesterol levels information centocor licenses remicade licensed manufactured centocor inc johnson johnson company scheringplough exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody currently phase iii trials scheringplough exclusive marketing rights products outside us japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending scheringploughs rights exclusively market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits scheringploughs distribution products scheringplough marketing territory share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products conditioned approval golimumab granted prior september scheringplough may independently develop market golimumab crohns disease indication territories option centocor participate table contents global operations majority scheringploughs operations outside us acquisition obs late scheringploughs global operations human prescription pharmaceuticals animal health increased nonus activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition scheringplough represented markets licensees distribution arrangements currently scheringplough business operations countries additional information global operations see item managements discussion analysis financial condition results operations segment information described k net sales geographic area dollars millions united states europe canada latin america pacific area asia consolidated net sales scheringplough subsidiaries countries outside us net sales presented geographic area scheringploughs customers located following countries accounted percent consolidated net sales past three years consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions total international net sales france japan canada italy net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions mckesson corporation cardinal health table contents supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows mount pe rcentage dollars millions us nasonex otc claritin international remicade scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting longlived assets geographic location dollars millions united states netherlands ireland singapore total longlived assets shown geographic location primarily intangibles property significant increase longlived assets december due obs acquisition scheringplough disaggregate assets segment basis internal management reporting therefore information presented research development scheringploughs research activities primarily aimed discovering developing new prescription products enhancements existing human prescription products medical commercial significance however scheringploughs research development platform also supports animal health consumer health care products often research development project application one product segment companysponsored research development expenditures billion billion billion respectively percentage consolidated net sales research development expenditures represented approximately percent percent percent respectively scheringploughs research activities concentrated six therapeutic areas focus cardiovascular central nervous system immunology infectious disease oncology respiratory womens health scheringplough also substantial efforts directed toward biotechnology vaccine development immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale scheringploughs product pipeline lists significant products development available scheringploughs website wwwscheringploughcom due nature development approval process well fact human table contents health involved science human health constantly evolving status compounds development subject change scheringplough assume duty update information scheringplough several research development projects granted fasttrack designation fda including novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular events boceprevir protease inhibitor compound hepatitis c vicriviroc ccr receptor antagonist treatment hiv aa adenosine receptor antagonist treatment parkinsons disease products two phase iii clinical testing phase thrombin receptor antagonist vicriviroc significant expenditures would required progress development due large number patients necessary phase iii trials research development expenses expected continue increase next several years primary reason schering ploughs pipeline larger new management team focused making research development productive additional pipeline projects added obs acquisition reasons include need larger clinical trials frequent clinical trials longer clinical trials current global regulatory environment research development activities typically continue product marketed one reason learn new indications product another reason respond safety effectiveness benefits risks may become known people use product longer period time patents trademarks intellectual property rights overview intellectual property protection critical scheringploughs ability successfully commercialize product innovations schering plough owns applied licensed rights large number patents us countries relating compounds formulations uses manufacturing processes assurance patents scheringplough seeking granted patents scheringplough granted would found valid challenged moreover patents relating particular formulations uses processes preclude manufacturers employing alternative processes marketing alternative formulations uses might successfully compete scheringploughs patented products outside us standard intellectual property protection pharmaceuticals varies widely many countries reasonably strong patent laws countries currently provide little effective protection inventions intellectual property rights traderelated aspects intellectual property agreement trips administered world trade organization wto countries agreed provide nondiscriminatory protection pharmaceutical inventions assure adequate effective rights available patent owners possible changes agreement made future diminish delay implementation developing countries soon assess much scheringplough impacted commercially changes product patent expires patent holder often loses effective market exclusivity product result rapid sharp material decline sales formerly patented product particularly us however cases innovator company obtain additional commercial benefits manufacturing trade secrets laterexpiring patents processes uses formulations trademark use exclusivity may available pharmaceutical regulatory laws scheringploughs intellectual property portfolio patent protection certain scheringplough compounds formulations processes uses important scheringploughs business financial results many scheringploughs products addition patents compound scheringplough holds patents manufacturing processes formulations uses may extend exclusivity beyond expiration compound patent table contents scheringploughs subsidiaries licensed rights number patents patent applications us abroad patents patent applications relating scheringploughs significant products including without limitation vytorin zetia remicade nasonex follistimpuregon nuvaring temodar pegintron clarinex material importance scheringplough worldwide scheringplough sells major products trademarks also material aggregate business financial results trademark protection varies throughout world protection continuing countries long mark used countries long registered registrations normally fixed renewable terms patent challenges hatchwaxman act drug price competition patent term restoration act commonly known hatchwaxman made complex set changes patent new drug approval laws us hatchwaxman drug could approved without providing us food drug administration fda complete safety efficacy studies known complete new drug application nda hatch waxman authorized fda approve generic versions innovative medicines without information upon filing abbreviated new drug application anda anda generic manufacturer must demonstrate bioequivalence generic version ndaapproved drug safety efficacy hatchwaxman provides limited patent term restoration partially make patent term lost time ndaapproved drug regulatory review ndaapproved drugs also receive limited period data exclusivity prevents approval anda applications specific time periods approval ndaapproved drug absent successful patent challenge fda approve anda innovators patents expire however generic manufacturer may file anda seeking approval expiration applicable data exclusivity alleging one patents listed innovators nda invalid infringed allegation commonly known paragraph iv certification innovator must file suit generic manufacturer protect patents one ndalisted patents successfully challenged first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue scheringploughs ks qs include listing hatchwaxman act challenges patents legal proceedings section marketing activities competition scheringplough trained professional sales representatives introduces makes known prescription drugs physicians pharmacists hospitals managed care organizations buying groups scheringplough sells prescription drugs hospitals certain managed care organizations wholesale distributors retail pharmacists scheringplough also introduces makes known prescription products journal advertising direct mail advertising distribution samples physicians television radio internet print advertising media scheringplough trained professional sales representatives promotes animal health products veterinarians distributors animal producers scheringplough sells overthecounter otc foot care sun care products wholesale retail drug food chain mass merchandiser outlets scheringplough promotes directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies significantly larger scheringplough substantial resources research product development advertising promotion field selling support table contents numerous domestic international competitors industry principal competitive techniques used scheringplough products include research development new improved products varied dosage forms strengths switching prescription products nonprescription status us many scheringploughs products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental thirdparty payers practices us pharmacists pressures toward dispensing generic products may significantly reduce sales certain products competing products therapeutic category longer protected patents exclusivity available pharmaceutical regulatory laws scheringplough operates primarily prescription pharmaceutical marketplace however appropriate scheringplough seeks regulatory approval switch prescription products overthecounter status means extending products life cycle way otc marketplace another means maximizing return investments discovery development government regulation scheringploughs major business segments subject significant regulation multiple jurisdictions section describes general regulatory framework additional information cost regulatory compliance specific impacts scheringploughs business financial condition described heading regulatory competitive environment scheringplough operates managements discussion analysis later k additional information regulatory matters found note legal environmental regulatory matters item financial statements supplementary data prescription drug segment regulations apply phases business including regulatory requirements conduct standards clinical trials example requiring use good clinical practices gcps apply research development stage regulatory requirements conduct standards postapproval clinical trials required regulatory approval begin marketing new drug market existing drug product new indications regulations prescribing manner drugs manufactured packaged labeled advertised marketed distributed regulations impacting pricing drugs regulatory requirements assess report adverse impacts side effects drugs used clinical trials well marketed drugs called pharmacovigilance ability regulatory authorities remove product market recall certain batches products us national regulation phases prescription drug business except pricing centralized food drug administration fda fda responsible protecting us public health assuring safety efficacy security human veterinary drugs biological products medical devices generally free market pricing us although centers medicare medicaid services cms medicare part b include provisions pricing drugs elderly disabled indigent receive federal prescription benefits scheringplough also committed complying voluntary best practices pharmaceutical research manufacturers america phrma trade industry group member regarding marketing advertising practices eu including scheringploughs key markets united kingdom france germany italy regulation local country level additional regulation eu level european medicines agency emea pharmaceutical products regulated levels various national mutual recognition centralized regulatory procedures emea coordinates evaluation table contents supervision medicinal products throughout eu paneu market pricing system however individual member states various systemsagencies regulate price local level japan regulation pharmaceuticals medical device agency pmda pmda regulates pharmaceuticals medical devices development postmarketing use japanese government regulates pricingreimbursement pharmaceutical products japan complicated pricing process includes benchmarks prices western countries united states canada select eu countries major countries influence pricing even cms united states increasing pressure pharmaceutical industry bring products market provide differentiation versus existing products lead expensive scientifically challenging clinical trials order generate type data new products versus marketed comparators raw materials raw materials essential scheringploughs operations available adequate quantities number potential suppliers energy expected available scheringplough sufficient quantities meet operating requirements seasonality certain scheringploughs products particularly respiratory sun care products seasonal nature seasonal patterns pronounced effect consolidated operations scheringplough environment date compliance federal state local laws regarding discharge materials environment protection environment material effect scheringploughs operations financial position employees december scheringplough employed approximately people worldwide available information scheringploughs ks qs ks amendments reports filed furnished sec available free charge scheringploughs website soon reasonably practicable materials electronically filed sec schering ploughs internet address wwwscheringploughcom since scheringplough began practice third quarter report available scheringploughs website within hours filing reports filed scheringplough sec may read copied secs public reference room f street ne washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxies information statements information regarding issuers file electronically sec item risk factors scheringploughs future operating results cash flows may differ materially results described k due risks uncertainties related scheringploughs business including discussed addition factors represent risks uncertainties could cause actual results differ materially implied forwardlooking statements contained report table contents key scheringplough products generate significant amount scheringploughs profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows scheringploughs ability generate profits operating cash flow depends largely upon continued profitability schering ploughs cholesterol franchise consisting vytorin zetia addition key products remicade nasonex pegintron temodar clarinex avelox account material portion revenues result scheringploughs dependence key products events adversely affects markets products could significant impact results operations events include loss patent protection increased costs associated manufacturing generic otc availability schering ploughs product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason example profitability scheringploughs cholesterol franchise may adversely affected competition multiple generic cholesterol products fda held public meeting solicit comment making certain prescription drugs available behindthe counter without prescription continues study scenario although fda indicate drugs might included category fda approved behindthecounter sales products compete products scheringplough merckschering plough cholesterol joint venture competition could adverse result sales profitability high risk funds invested research generate financial returns development novel drugs requires significant expenditures low probability success high rate failure inherent research develop new drugs treat diseases result high risk funds invested research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested scheringploughs success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others intellectual property protection innovation important contributor scheringploughs profitability generic forms scheringploughs products may introduced market result expiration patents covering scheringploughs products successful challenge scheringploughs patents atrisk launch generic version scheringplough product may material negative effect results operations intellectual property protection critical scheringploughs ability successfully commercialize products us patents relating scheringploughs significant products material importance scheringplough upon expiration successful challenge scheringploughs patents covering table contents product competitors may introduce lowerpriced generic similar branded versions product may include scheringploughs wellestablished products generic manufacturer may file abbreviated new drug application seeking approval expiration applicable data exclusivity alleging one patents listed innovators new drug application invalid infringed unenforceable allegation commonly known paragraph iv certification innovator ability file suit generic manufacturer enforce patents generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue recent years generic manufacturers launched generic versions products ultimate resolution patent litigation commonly known atrisk product launches generic entry may result loss significant portion sales downward pressures prices scheringplough offers formerly patented products please refer legal proceedings scheringploughs k qs descriptions pending intellectual property litigation additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect scheringploughs results operations recent court decisions relating companies patents us potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection patent disputes costly prosecute defend adverse judgments could result damage awards increased royalties similar payments decreased sales patent positions highly uncertain patent disputes pharmaceutical industry unusual adverse result patent dispute involving scheringploughs patents patents collaborators may lead determination court patent infringed invalid andor unenforceable adverse determination could lead loss market exclusivity adverse result patent dispute involving patents held third party may lead determination court patent infringed valid enforceable adverse determination may preclude commercialization scheringploughs products injunctive relief andor may lead significant financial damages past ongoing infringement due uncertainty surrounding patent litigation parties may settle patent disputes obtaining license mutually agreeable terms order decrease risk interruption manufacturing andor marketing products potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights even scheringplough ultimately successful particular dispute scheringplough may incur substantial costs defending patents intellectual property rights see patent challenges hatchwaxman act item legal proceedings list current paragraph iv certifications scheringplough products multijurisdictional regulations including establishing scheringploughs ability price products may negatively affect scheringploughs sales profit margins scheringplough faces increased pricing pressure globally managed care organizations institutions government agencies programs could negatively affect scheringploughs sales profit margins example us medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulted increased use generics increased purchasing power negotiating behalf medicare recipients addition legislation concerning price controls trends could affect scheringploughs business trends include legislative regulatory action relating pharmaceutical pricing reimbursement health care reform initiatives drug importation legislation involuntary approval medicines otc use trends also include nongovernmental initiatives practices consolidation among customers managed care practices health care costs containment increasingly market approval table contents reimbursement products prescribers practices policies third party payors may influenced health technology assessments national institute health clinical excellence uk organizations us result governments efforts reduce medicaid expenses managed care organizations continue grow influence scheringplough faces increased pricing pressure managed care organizations continue seek price discounts respect scheringploughs products countries many governmental agencies strictly control directly indirectly prices pharmaceutical products sold markets cost control methods including restrictions physician prescription levels patient reimbursements emphasis greater use generic drugs acrosstheboard price cuts may decrease revenues internationally acquisition obs scheringplough acquired marketed products pipeline projects therapeutic areas currently covered scheringploughs existing marketed products portfolio pipeline projects including womens health fertility anesthesia neuroscience carry unique risks uncertainties could negative impact future results operations acquisition obs scheringplough acquired products additional therapeutic areas therapeutic area presents different risk profile including different benefits safety issues must balanced scheringplough regulators various rd marketing decisions made unique product liability risks different patient prescriber priorities different societal pressures adding new therapeutic areas may strengthen business increasing sales profits making combined company relevant patients prescribers diversifying enterprise risk across areas positives may outweigh additional risk particular therapeutic area could result unanticipated costs could material market forces continue evolve impact scheringploughs ability sell products price scheringplough charge products number intermediaries involved drug manufacturers scheringplough patients use drugs intermediaries impact patients ability prescribers ability choose pay particular drug intermediaries include health care providers hospitals clinics payors representatives employers insurers managed care organizations governments others supply chain pharmacists wholesalers examples include payors require patient first fail generic drug reimbursing effective branded product expensive hospitals stock administer generic product inpatients managed care organizations may penalize doctors prescribe outside approved formularies may include branded products generic available pharmacists receive larger revenues dispense generic drug branded drug intermediaries required routinely provide transparent data patients comparing effectiveness generic branded products disclose economic benefits tied steering patients toward requiring patients use generic products rather branded products government investigations scheringplough could lead commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs could give rise investigations litigation government entities private parties scheringplough predict whether future pending investigations may become subject would lead judgment settlement involving significant monetary award restrictions operations pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department table contents justice us attorneys offices office inspector general department health human services fda federal trade commission various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs addition adverse outcome government investigation could prompt government entities commence investigations scheringplough cause entities private parties bring civil claims scheringplough also predict whether investigations affect marketing practices sales result could material adverse impact schering ploughs results operations cash flows financial condition business congress certain states initiated investigations timing disclosure enhance clinical trial related events well timing certain stock sales one executive officer carrie cox regardless merits outcomes investigation government investigations costly divert managements attention scheringploughs business may result substantial damage scheringploughs reputation legal matters adverse outcomes could negatively affect scheringploughs business unfavorable outcomes pending litigation matters future litigation including litigation concerning product pricing securities law violations product liability claims erisa matters patent intellectual property disputes antitrust matters could preclude commercialization products negatively affect profitability existing products could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs result could materially adversely affect scheringploughs results operations cash flows financial condition business please refer legal proceedings item k descriptions significant pending litigation issues concerning merckscheringplough cholesterol joint ventures enhance clinical trial could material adverse effect joint ventures sales vytorin zetia turn could material adverse impact scheringploughs financial condition see item legal proceedings enhance matter background information merckscheringplough cholesterol join ventures enhance clinical trial related matters issues concerning merckscheringplough cholesterol joint ventures enhance clinical trial could material adverse effect merckscheringplough cholesterol joint ventures sales vytorin zetia significant negative media surrounding release topline results date ims data shows prescriptions vytorin zetia declined sales products continue trend remain current levels prolonged period scheringploughs business cash flow results operations financial position prospects could also materially adversely affected addition unfavorable outcomes resulting government investigations litigation concerning sale promotion products could material adverse effect scheringploughs financial position liquidity results operations table contents scheringplough subject governmental regulations failure comply well costs compliance regulations may adversely affect scheringploughs financial position results operations scheringploughs manufacturing facilities clinicalresearch practices must meet stringent regulatory standards subject regular inspections cost regulatory compliance including associated compliance failures materially affect schering ploughs financial position cash flows results operations failure comply regulations include pharmacovigilance reporting requirements standards relating clinical laboratory manufacturing practices result delays approval drugs seizure recalls drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions scheringplough also subject regulations including environmental health safety labor regulations developments following regulatory approval may adversely affect sales scheringploughs products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials may decrease demand scheringploughs products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed uncertainties concerning safety labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products situations also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials lead increase volatility market reaction addition following wake recent product withdrawals companies significant safety issues health authorities fda european medicines agency pharmaceuticals medicines device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially us advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase prevalence negative publicity regarding known side effects scheringploughs products could significantly reduce demand product may require scheringplough remove product market current environment pharmaceutical companies operate scheringplough risk product liability claims products new products technological advances developed scheringploughs competitors may negatively affect sales scheringplough operates highly competitive industry scheringplough competes large number multinational pharmaceutical companies biotechnology companies generic pharmaceutical companies many scheringploughs competitors conducting research development areas served scheringploughs current products products scheringplough process table contents developing competitive developments may impact scheringplough include technological advances patents granted new products developed competitors new existing generic prescription andor otc products compete products schering plough merckscheringplough cholesterol joint venture addition possible doctors patients providers may favor products offered competitors due safety efficacy pricing reimbursement characteristics result scheringplough unable maintain sales products competition third parties may make difficult scheringplough acquire license new products product candidates regardless stage development enter transactions terms permit scheringplough generate positive financial impact scheringplough depends acquisition inlicensing arrangements source new products opportunities obtaining licensing new products limited however securing rights typically requires substantial amounts funding substantial resource commitments scheringplough competes opportunities many companies third parties greater financial resources greater ability make resource commitments scheringplough may able acquire license new products could adversely impact scheringplough prospects scheringplough may also difficulty acquiring licensing new products acceptable terms secure rights new products scheringplough may make substantial financial resource commitments could limit ability produce positive financial impact transactions scheringplough relies thirdparty relationships key products conduct changing circumstances third parties may adversely impact business scheringplough several relationships third parties scheringplough depends many key products often third parties compete scheringplough interests aligned interests scheringplough notwithstanding contracts scheringplough third parties scheringplough may able control influence conduct parties circumstances affect either could adversely impact scheringplough relationships longstanding third partys work scheringploughs work evolves priorities alignments also change times new issues develop anticipated time contracts negotiated new issues related uncertainties contracts also adversely impact scheringplough scheringploughs global operations expose scheringplough additional risks adverse event could material negative impact results operations majority scheringploughs operations outside us acquisition obs late scheringploughs global operations human prescription pharmaceuticals animal health increased acquisitions recently completed purchase obs expanded size scale scope global operations risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict scheringploughs ability manufacture sell products key markets trade protection measures import export licensing requirements diminished protection intellectual property countries possible nationalization expropriation addition may changes scheringploughs business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease table contents integration businesses scheringplough obs create combined company complex process may subject unforeseen developments could impact anticipated cost savings synergies expected accretion earnings results future operations two companies combined workforces scheringplough obs continue face uncertainties completion integration phase although substantial efforts made complete integration phase quickly possible difficult predict long integration phase last workforces companies learning use new processes work integrated streamlined employees new combined company past worked usbased global company applicable regulatory requirements different number respects substantial efforts made facilitate smooth execution integration including thorough training transparent motivational employee communications may increased risk slower execution various work processes repeated execution achieve quality standards reputational harm event compliance failure new complex regulatory requirements even failure inadvertent events could adverse impact anticipated cost savings synergies anticipated accretion earnings transaction results future operations acquisition obs expanded scheringploughs animal health business worldwide increases risk negative events animal health industry could negative impact future results operations acquisition obs animal health businesses scheringploughs global animal health business significant business segment combined companys future sales key animal health products could adversely impacted number risk factors including certain specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy bse mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact scheringploughs results operations also outbreak highly contagious diseases near scheringploughs main production sites could require scheringplough immediately halt production vaccines sites force scheringplough incur substantial expenses procuring raw materials vaccines elsewhere animal health segment scheringploughs business becomes significant impact events future results operations would also become significant acquisition obs increased scheringploughs biologics human animal health product offerings including animal health vaccines biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions us european states within eu could result restricted access transport use materials scheringplough loses access sufficient sources materials tighter restrictions imposed use materials scheringplough may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda european medicines agency regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example us biologics license application including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval release manufactured lot table contents manufacturing biologics especially large quantities sometimes complex may require use innovative technologies handle living microorganisms manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs scheringplough exposed market risk fluctuations currency exchange rates interest rates scheringplough operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally scheringplough entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since scheringplough certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect scheringploughs results operations andor cash flows order mitigate adverse impact market fluctuations scheringplough time time enter hedging agreements hedging agreements currency options interest rate swaps limit exposure exchange rate interest rate fluctuations attempts mitigate risks costly always successful insurance coverage product liability may limited cost prohibitive unavailable scheringplough maintains insurance coverage deductibles selfinsurance reflect market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly certain products thirdparty insurance may cost prohibitive available limited terms unavailable scheringplough subject evolving complex tax laws may result additional liabilities may affect results operations scheringplough subject evolving complex tax laws jurisdictions significant judgment required determining schering ploughs tax liabilities scheringploughs tax returns periodically examined various tax authorities scheringploughs tax returns remain open examination irs scheringplough may challenged irs tax authorities positions taken income tax returns although scheringplough believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued acquisition obss organon human pharmaceutical intervet animal health businesses main tax risks correspondingly centered netherlands management intellectual property beneficial rights well product liability predominantly centered tax position organon intervet netherlands closed addition scheringplough may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions table contents item b unresolved staff comments none item properties scheringploughs corporate global human pharmaceutical headquarters located kenilworth new jersey animal health global headquarters located boxmeer netherlands principal us research facilities located kenilworth union summit new jersey palo alto california nebraska animal health principal research facilities outside us located netherlands scotland principal manufacturing facilities follows location product type belgium pharmaceuticals brazil pharmaceuticals animal health cleveland tennessee usa consumer products france pharmaceuticals ireland pharmaceuticals consumer products animal health kenilworth new jersey usa pharmaceuticals consumer products mexico pharmaceuticals millsboro delaware usa animal health netherlands pharmaceuticals animal health omaha nebraska usa animal health puerto rico pharmaceuticals research triangle park north carolina usa pharmaceuticals singapore pharmaceuticals scheringplough owns majority properties general properties adequately maintained suitable purposes discussed detail part ii k certain scheringploughs manufacturing sites operate capacity scheringplough currently process building us pharmaceutical sciences center new jersey capital expenditures approximately million million made respectively related center additional capital expenditures approximately million expected next two years item legal proceedings material pending legal proceedings ordinary routine litigation incidental business scheringplough corporation subsidiaries property subject disclosed additional information legal proceedings including important financial information found litigation charges discussion item managements discussion analysis financial condition results operations note special acquisition related charges manufacturing streamlining note legal environmental regulatory matters contained item financial statements supplementary data enhance matter background merckscheringplough cholesterol joint venture markets zetia vytorin combination mercks zocor simvastatin scheringploughs zetia ezetimibe merckscheringplough cholesterol joint ventures enhance effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia clinical trial surrogate endpoint trial conducted patients table contents heterozygous familial hypercholesterolemia rare condition affects approximately population primary endpoint mean change intimamedia thickness measured three sites carotid arteries right left common carotid internal carotid carotid bulb patients treated ezetimibesimvastatin mg versus patients treated simvastatin mg alone twoyear period statistically significant difference treatment groups primary endpoint components primary endpoint including common carotid artery key secondary imaging endpoints also showed statistical difference treatment groups january merckscheringplough cholesterol joint venture announced topline results enhance clinical trial fuller discussions results enhance clinical trial medical scientific forums customary discussion scheduled american college cardiology meeting march technical difficulties analyzing sometimes fuzzy ultrasound images consumed long time period since last patient scanned april december data ultrasound images first unblinded scientists merckscheringplough cholesterol joint venture analysis results summary findings released joint venture january media speculation length time needed analyze ultrasound images media confusion meaning trial results medical experts health advisory groups long recognized high ldl cholesterol significant cardiovascular risk factor recommended increasingly aggressive treatment high cholesterol certain patients lowering ldl cholesterol along healthy diet lifestyle changes remains cornerstone lipid treatment patients risk heart disease clinical studies prior enhance demonstrated vytorin lowered patients ldl cholesterol rosuvastatin atorvastatin simvastatin doses studied able get patients ldl cholesterol goals defined atp iii findings merckscheringplough cholesterol joint ventures enhance clinical trial confirmed vytorins effectiveness compared simvastatin lowering ldl cholesterol specifically significant difference lowdensity lipoprotein ldl cholesterol lowering seen treatment groups ldl cholesterol lowering months ezetimibesimvastatin compared months simvastatin alone enhance surrogate endpoint study powered designed assess cardiovascular clinical event outcomes effectiveness drugs lowering risk heart attack stroke merckscheringplough cholesterol joint venture currently conducting improveit trial large clinical trial comparing vytorin ezetimibesimvastatin simvastatin patients results improveit trial compare effectiveness vytorin simvastatin alone reducing heart attacks andor strokes scheringploughs stock price declined significantly early closing price december low closing price january closing price february day k filed investigations date filing k scheringplough joint venture andor joint venture partner merck co inc merck received several letters congress including house committee energy commerce house subcommittee oversight investigations ranking minority member senate finance committee collectively seeking combination witness interviews documents information variety issues related merckscheringplough cholesterol joint ventures enhance clinical trial companies sale promotion vytorin well sales stock table contents companies corporate officers including one executive scheringplough named one letters carrie cox since april several subpoenas state officials state attorney general state department justice several states including connecticut new york oregon seeking similar information documents scheringplough cooperating investigations working merck respond inquiries litigation addition since midjanuary scheringplough become aware served litigation including civil class action lawsuits alleging common law state consumer fraud claims connection scheringploughs sale promotion merckscheringplough jointventure products vytorin zetia several putative shareholder securities class action lawsuits several officers also named defendants alleging false misleading statements omissions scheringplough representatives related timing disclosures concerning enhance results allegedly violation sections b securities exchange act shareholder derivative action alleging board directors breached fiduciary obligations relating timing release enhance results letter behalf single shareholder requesting board directors investigate allegations putative securities class actions warranted bring appropriate legal action behalf scheringplough scheringplough cooperating fully government investigations intends vigorously defend lawsuits filed relating enhance study patent matters described patents trademarks intellectual property rights item business k intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect schering plough dr scholls freeze away july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product matter settled material impact scheringploughs financial statements stipulation dismissing action filed parties february patent challenges hatchwaxman act scheringplough currently believe pending paragraph iv certification proceeding hatchwaxman act material frequently media investor interest proceedings scheringplough listing pending proceedings quarter currently following pending july scheringplough licensor cancer research technologies limited filed patent infringement action companies seeking approval generic version certain strengths temodar capsules march scheringplough entity jointly owned merck filed patent infringement action companies seeking approval generic version zetia september dates thereafter scheringplough filed patent infringement actions companies seeking approval generic versions clarinex tablets clarinex reditabs clarinex clarinex table contents awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege schering plough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks compensatory damages behalf class court certified shareholder class october notice pendency class action sent members class july discovery completed motions summary judgment briefed pending erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anti competitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws table contents well state statutory common law causes action suits seek unspecified damages discovery ongoing thirdparty payor actions several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently tried newark district court scheringploughs tax reserves adequate cover abovementioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection settlement massachusetts investigation commencing new fiveyear term failure comply obligations cia could result financial penalties matters products liability beginning may number complaints filed various jurisdictions asserting claims organon usa inc organon pharmaceuticals usa inc andor organon international organon arising scheringploughs marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages heart attacks strokes majority cases currently pending united states district court district new jersey cases pending wisconsin missouri new york georgia french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court april competitor also requested interim relief portion granted french competition authority december interim relief required scheringploughs french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority table contents item submission matters vote security holders applicable executive officers registrant listed executive officers corporate officers scheringplough february unless otherwise indicated held position indicated past five years officers serve one year successors duly appointed name title ag e robert j bertolini executive vice president chief financial officer john carroll vice president global internal audits c ron cheeley senior vice president global human resources carrie cox executive vice president president global pharmaceuticals william j creelman vice president tax fred hassan chairman chief executive officer steven h koehler vice president controller thomas p koestler phd executive vice president president scheringplough research institute raul e kohan senior vice president corporate excellence joseph j larosa vice president legal affairs ian mcinnes senior vice president president global supply chain e kevin moore vice president treasurer lori queisser senior vice president global compliance business practices thomas j sabatino jr executive vice president general counsel karl salnoske vice president chief information officer brent saunders senior vice president president consumer health care corporate secretary associate general counsel vice president corporate susan ellen wolf governance officers defined rule af securities exchange act mr bertolini joined scheringplough executive vice president chief financial officer mr bertolini partner pricewaterhousecoopers mr carroll joined scheringplough vice president global internal audits mr carroll vice president general auditor american standard companies general auditor american standard companies assistant treasurer bristolmyers squibb mr cheeley joined scheringplough senior vice president global human resources mr cheeley group vice president global compensation benefits pharmacia corporation ms cox joined scheringplough executive vice president president global pharmaceuticals ms cox executive vice president president global prescription business pharmacia corporation mr creelman joined scheringplough vice president tax mr creelman senior tax counsel pfizer mr creelman assistant vice president international tax cigna corporation table contents mr hassan joined scheringplough chairman board chief executive officer mr hassan chairman board chief executive officer pharmacia corporation mr koehler joined scheringplough vice president controller mr koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicines company dr koestler named executive president president scheringplough research institute september dr koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affairs pharmacia corporation mr larosa became vice president legal affairs mr larosa staff vice president secretary associate general counsel dr mcinnes joined scheringplough senior vice president global supply chain dr mcinnes senior vice president global supply chain pharmacia corporation executive vice president supply chain watson pharmaceuticals inc ms queisser joined scheringplough february senior vice president global compliance business practices ms queisser vice president chief compliance officer october february executive director general auditor march october eli lilly company mr sabatino joined scheringplough executive vice president general counsel mr sabatino senior vice president general counsel baxter international inc mr salnoske joined scheringplough vice president chief information officer mr salnoske ceo adaptive trade mr saunders joined scheringplough senior vice president global compliance business practices mr saunders partner pricewaterhousecoopers ms wolf named vice president corporate secretary associate general counsel held various positions scheringploughs law department part ii item market registrants common equity related stockholder matters principal market scheringploughs common stock new york stock exchange additional information required item incorporated reference table captioned quarterly data unaudited item financial statements supplementary data table contents following table provides information respect purchases scheringplough common shares fourth quarter issuer purchases equity securities total number aximum number shares purchased shares may average part publicly yet purchased total number price paid announced plans plans period shares purchased per share programs programs october october na na november november na na december december na na total october december na na shares included table repurchased pursuant scheringploughs stock incentive program represent shares delivered scheringplough option holders payment exercise price tax withholding obligations connection stock options stock awards performance graph comparison cumulative total return five years ended december scheringplough corporation composite peer group sp index graph assumes investment december reinvestment dividends scheringploughs common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck co inc pfizer inc wyeth table contents item selected financial data millions except per share figures percentages operating results net sales equity income lossincome income taxes net lossincome net lossincome available common shareholders diluted lossearnings per common share basic lossearnings per common share research development expenses acquired inprocess research development depreciation amortization expenses financial position cash flows property net total assets longterm debt shareholders equity capital expenditures financial statistics net lossincome percent net sales return average shareholders equity net book value per common share data cash dividends per common share cash dividends paid common shares cash dividends preferred shares average shares outstanding used calculating diluted earningsloss per common share average shares outstanding used calculating basic earningsloss per common share common shares outstanding yearend operating results financial information reflects closing obs acquisition november including impacts purchase accounting accordance sfas business combinations include special acquisition related charges manufacturing streamlining costs respectively see note special acquisition related charges manufacturing streamlining additional information charges incurred special charges incurred included million employee termination costs million asset impairment related charges special charges included increases litigation reserves million resulted investigations scheringploughs sales marketing practices approximately million employee termination costs related voluntary early retirement program announced august million asset impairment charges increase longterm debt primarily reflects financing obs acquisition table contents assumes conversion mandatory convertible preferred stock approximately million common shares assumes conversion mandatory convertible preferred stock approximately million common shares million common shares million common shares item managements discussion analysis financial condition results operations executive summary overview scheringplough scheringplough innovationdriven sciencecentered global health care company scheringplough discovers develops manufactures pharmaceuticals three customer markets human prescription animal health consumer research development activity directed toward prescription products important applications central research development platform animal health products consumer health care products scheringplough also accesses external innovation via partnering inlicensing acquisition three customer markets strategy focused science earlier decade scheringplough experienced number business regulatory legal challenges april board directors named fred hassan new chairman board chief executive officer scheringplough corporation support board initiated strategic plan goal stabilizing repairing turning around scheringplough order build longterm shareholder value also installed new senior executive team strategic plan action agenda six eightyear fivephase plan scheringplough currently fourth phase action agenda build base build base phase scheringplough continues focus strategy value creation across broad front believes organon biosciences nv obs acquisition major transformative accomplishment regard obs acquisition added diversification marketed products including two new therapeutic areas womens health central nervous system well significant strength animal health products pipeline accomplishments include growing business example double digit sales growth three product groups human pharmaceuticals animal health consumer health care penetrating new markets including china brazil russia expanding product portfolio scheringploughs three customer groups human pharmaceutical animal health consumer health care discovering developing acquiring new products key component action agenda applying science meet unmet medical needs research development activities focus mechanisms treat serious diseases result core strategy scheringplough invest substantial funds scientific research goal creating therapies treatments address important unmet medical needs also commercial value scheringplough successful advancing pipeline several latestage projects require sizable resources complete consistent core strategy scheringplough increasing investment research development scheringplough continues develop later phase growthdrivers pipeline eg sugammadex thrombin receptor antagonist golimumab vicriviroc boceprevir asenapine anticipates higher spending clinical trial activities scheringploughs progressing early pipeline includes drug candidates across wide range therapeutic areas compounds approaching phase development part action agenda scheringplough continues work enhance infrastructure upgrade processes systems strengthen talent recruitment talented individuals development key employees efforts implemented companywide basis scheringplough focusing especially research development support scheringploughs sciencebased business table contents integration obs employees scheringplough much new talent added addition part integration obs scheringplough also announced workforce reduction eliminate redundancies results highlights scheringploughs performance follows closed acquisition obs november purchase price approximately euro billion scheringploughs net sales billion increase billion percent compared period net sales included million sales products acquired part obs acquisition net loss available common shareholders billion compared net income available common shareholders billion included net loss approximately billion charges related purchase accounting obs acquisition including billion acquired inprocess research development charge cash flow provided operating activities billion global sales scheringploughs cholesterol franchise products vytorin zetia made cholesterol joint venture merck company inc merck continued grow contributed significantly scheringploughs improved operating results cash flow see note developments addition increased sales pharmaceutical products remicade temodar nasonex also contributed favorably scheringploughs overall operating results cash flow additional strength scheringplough developed four years since mr hassan new management team began action agenda key scheringplough current environment pharmaceutical industry continues subject evermore critical scrutiny events mischaracterized drive amplified reactions scheringplough believes new scientific data best presented discussed appropriate scientific medical forums early developments relating cholesterol franchise explained detail part item legal proceedings enhance matter early scheringplough encountered challenge results merckscheringplough cholesterol joint venture clinical trial called enhance joint venture products zetia vytorin became subject much media scrutiny prior fuller discussions trial results appropriate medical forums discussion scheduled american college cardiology meeting march medical experts health advisory groups long recognized high ldl cholesterol often known bad cholesterol significant cardiovascular risk factor recommended increasingly aggressive treatment high cholesterol certain patients lowering ldl cholesterol along healthy diet lifestyle changes remains cornerstone lipid treatment patients risk heart disease clinical studies including enhance demonstrated vytorin lowers patients ldl cholesterol rosuvastatin atorvastatin simvastatin doses studied able get patients ldl cholesterol goals defined atp iii early tell impact joint ventures enhance trial results joint ventures cholesterol business schering ploughs diversified group products geographic areas well highly experienced executive team gives scheringplough additional strength helpful weathering situation strategic alliances typical pharmaceutical industry scheringplough licenses manufacturing marketing andor distribution rights certain products others also manufactures markets andor distributes products table contents owned others pursuant licensing joint venture arrangements time third parties involved additional factors relating third party outside control scheringplough may create positive negative impacts scheringplough vytorin zetia remicade subject arrangements key scheringploughs current business financial performance addition potential strategic alternatives may impacted change control provisions arrangements could result vytorin zetia acquired merck remicade reverting back centocor change control provision relating vytorin zetia included contract merck filed exhibit r scheringploughs k change control provision relating remicade contained contract centocor filed exhibit v scheringploughs k cholesterol franchise scheringploughs cholesterol franchise products vytorin zetia managed joint venture scheringplough merck treatment elevated cholesterol levels markets outside japan zetia scheringploughs novel cholesterol absorption inhibitor vytorin combination zetia zocor simvastatin statin medication developed merck financial commitment compete cholesterol reduction market shared merck profits sales vytorin zetia also shared merck operating results joint venture merck recorded using equity method accounting cholesterolreduction market single largest pharmaceutical category world vytorin zetia competing market combined basis products continued grow terms sales market share see note developments material change sales market share scheringploughs cholesterol franchise would significant impact scheringploughs consolidated results operations cash flows order maintain enhance infrastructure business scheringplough must continue increase profits increased profitability largely dependent upon performance scheringploughs cholesterol franchise japan included joint venture merck japanese market bayer healthcare comarketing scheringploughs cholesterolabsorption inhibitor zetia approved japan april monotherapy coadministered statin use patients hypercholesterolemia familial hypercholesterolemia homozygous sitosterolemia zetia launched japan june scheringploughs sales zetia japan comarketing agreement bayer healthcare recognized net sales license arrangements centocor remicade prescribed treatment inflammatory diseases rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis remicade scheringploughs second largest marketed pharmaceutical product line cholesterol franchise remicade licensed manufactured centocor inc johnson johnson company scheringplough exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody currently phase iii trials scheringplough exclusive marketing rights products outside us japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending schering ploughs rights exclusively market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits scheringploughs distribution products scheringplough marketing territory share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products conditioned approval golimumab granted prior september scheringplough may independently develop table contents market golimumab crohns disease indication territories option centocor participate addition scheringplough centocor agreed utilize autoinjector device commercialization golimumab agreed share development costs rights device scheringplough made upfront payment million included research development expenses year ended december manufacturing sales marketing scheringplough supports commercialized products manufacturing sales marketing efforts scheringplough also moving forward additional investments enhance infrastructure business including capital expenditures drug development process products moved drug discovery pipeline markets information technology systems postmarketing studies monitoring scheringplough continually reviews business including manufacturing operations identify actions enhance longterm competitiveness however scheringploughs manufacturing cost base relatively fixed actions significantly reduce scheringploughs manufacturing infrastructure including obs manufacturing operations acquired involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements time time actions taken enhance scheringploughs overall manufacturing efficiency example scheringplough closed manufacturing plant puerto rico began process closing small manufacturing facility asia pacific region scheringplough continues review carrying value manufacturing assets indications impairment future events decisions may lead additional asset impairments related costs regulatory competitive environment scheringplough subject jurisdiction various national state local regulatory agencies regulatory compliance complex costly impacting timing needed bring new drugs market market drugs new indications scheringplough engages clinical trial research many countries around world research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eu member states clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products number intermediaries involved drug manufacturers scheringplough patients use drugs intermediaries impact patients ability precriberss ability choose pay particular drug intermediaries include health care providers hospitals clinics payors representatives employers insurers managed care organizations governments others supply chain pharmacists wholesalers us many scheringploughs pharmaceutical products subject increasingly competitive pricing certain intermediaries including managed care groups institutions government agencies seek price discounts international markets scheringplough operates environment government mandated costcontainment programs also pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors loss patent protection due challenges competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature table contents obs acquisition november scheringplough acquired obs purchase price approximately euro billion cash approximately billion commencing acquisition date obs assets acquired liabilities assumed well results obs operations included scheringploughs consolidated financial statements approximately one onehalf months results operations relating obs included scheringploughs statement consolidated operations year ended december impact purchase accounting based preliminary valuation resulted following noncash charges acquired inprocess research development iprd onetime charge approximately billion amortization inventory adjusted fair value approximately billion charged cost sales million approximately one year period acquisition date amortization acquired intangible assets adjusted fair value billion amortized weighted average life years cost sales million incremental depreciation relating adjustment fair value property plant equipment million depreciated primarily cost sales lives applicable property million billion acquired iprd charge associated research projects womens health central nervous system anesthesia therapeutic areas human health well research projects animal health amount determined using discounted cash flow projections identified research projects technological feasibility established alternative future use discount rates used ranged percent percent projected launch dates following fda regulatory approval years time scheringplough expects projects begin generate cash flows research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda regulatory approvals discussion operating results results operations discussed include obs product sales expenses well certain noncash charges relating purchase accounting associated obs acquisition net sales significant portion net sales made major pharmaceutical health care product distributors major retail chains us consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler retail trade buying decisions changes overall demand factors factors addition fluctuations sales many pharmaceutical products us subject increased pricing pressure managed care groups institutions government agencies groups seeking discounts scheringplough pharmaceutical manufacturers us market also required provide statutorily defined rebates various government agencies order participate medicaid program veterans health care program governmentfunded programs medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulting increased use generics increased purchasing power negotiating behalf medicare recipients international markets scheringplough operates environment governments may mandated costcontainment table contents programs placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs consolidated net sales billion increase billion percent compared consolidated net sales included million obs net sales related period subsequent acquisition increase also reflects growth sale volumes remicade temodar nasonex avelox well contributions animal health consumer health care favorable impact percent foreign exchange consolidated net sales billion increase billion percent compared increase primarily reflected growth sale volumes remicade nasonex pegintron temodar increase also reflected unfavorable impact percent foreign exchange net sales years ended december follows incre ase dec rease dollars millions human prescription pharmaceuticals remicade nasonex pegintron temodar clarinexaerius claritin rx avelox integrilin rebetol caelyx intron subutexsuboxone asmanex nm pharmaceutical animal health consumer health care otc nm foot care sun care consolidated net sales nm meaningful percentage sales human prescription pharmaceuticals totaled billion billion increase compared included million net sales related organon human health business obs sales human prescription pharmaceuticals totaled billion billion increase compared international net sales remicade drug treatment immunemediated inflammatory disorders rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis percent billion compared driven continued market growth expanded use across indications favorable impact foreign table contents exchange global net sales increased percent billion compared due greater demand expanded indications continued market growth competitive products indications referred introduced global net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies rose percent billion compared due increased sales across geographic regions percent million compared product captured greater us international market share competitive products introduced global net sales pegintron powder injection pegylated interferon product treating hepatitis c increased percent million compared due higher sales latin america emerging markets across europe tempered lower sales japan due increased competition decrease us market size global net sales increased percent million compared reflecting higher sales volume japan us japan sales benefited significant number patients waiting approval pegintron beginning treatment global net sales temodar capsules treatment certain types brain tumors increased percent million compared due increased sales across geographic markets including japan product launched september global net sales increased percent million compared due increased utilization new indications global net sales clarinex marketed aerius many countries outside us treatment seasonal outdoor allergies yearround indoor allergies increased percent million compared primarily due higher sales international markets global net sales increased percent million compared due increased demand europe latin america well increased sales us despite slightly declining market share international net sales prescription claritin increased percent million compared reflecting growth latin america asia pacific japan sales decreased percent million compared net sales avelox fluoroquinolone antibiotic treatment certain respiratory skin infections sold primarily us scheringplough result license agreement bayer increased percent million compared primarily result increased market share net sales increased percent million compared million due share growth new indications global net sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndrome sold primarily us scheringplough increased percent million compared sales increased percent million compared global net sales rebetol capsules use combination pegintron intron treating hepatitis c decreased percent million compared due lower patient enrollment japan increased generic competition global net sales decreased percent million compared due lower sales europe increased competition japan sales benefited significant number patients waiting approval pegintron beginning hepatitis c treatment international net sales caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increased percent million compared primarily due increased sales latin america favorable impact foreign exchange sales increased percent million compared primarily due expanding market product global net sales intron injection chronic hepatitis b c antiviral anticancer indications decreased percent million compared percent table contents million compared decrease due conversion pegintron treating hepatitis c japan international net sales subutexsuboxone treatment opiate addiction increased percent million compared result benefit foreign exchange sales increased percent million compared due increased market share october suboxone approved eu including member states well iceland norway treatment opioid dependence global net sales asmanex orally inhaled steroid asthma percent million compared primarily due market share growth us sales increased million compared due asmanex launch commencing late pharmaceutical net sales include net sales organon date acquisition december large number lower sales volume human prescription pharmaceutical products net sales organon million included million follistimpuregon fertility treatment million nuvaring contraception product also included pharmaceutical sales several lower volume products often sold limited markets outside us many multiple source products longer protected patents products include treatments respiratory cardiovascular dermatological infectious oncological diseases included pharmaceutical sales sales scheringploughs albuterol products fda issued final rule requires cfc albuterol products including scheringploughs proventil cfc removed market later december scheringploughs transition albuterol hfa proventil hfa complete scheringplough longer manufactures cfc product remaining cfc inventories sold scheringplough uncertain ultimate impact scheringploughs overall future sales proventil hfa due complexities multiple external factors influencing transition including competing albuterol hfa products global net sales animal health products increased percent billion compared included global animal health net sales million related intervet animal health business obs period subsequent acquisition global net sales also benefited solid growth geographic areas led cattle companion animal product lines coupled positive impact foreign currency exchange rates global net sales increased percent million compared reflecting strong growth core brands across geographic species areas led higher sales companion animal products animal health segments sales growth rate impacted intense competition frequent introduction generic products global net sales consumer health care products include otc foot care sun care products increased percent million compared increase primarily due sales miralax launched february first rxtootc switch laxative category years higher sales otc claritin global net sales increased percent million compared reflecting increase sales sun care products dr scholls foot care products sales otc claritin increased percent million compared due sales growth across product forms otc claritin sales decreased percent compared result restrictions retail sale otc products containing pseudoephedrine pse addition otc claritin continues face competition private labels branded loratadine competing prescription antihistamine launched otc sale early net sales sun care products increased million percent compared due coppertone continuous spray line extensions million percent compared primarily due success new coppertone continuous spray products launched future sales consumer health care segment difficult predict consumer health care market highly competitive heavy advertising consumers frequent competitive product introductions table contents costs expenses equity income summary costs expenses equity income years ended december follows incre se dec rease dollars millions gross margin selling general administrative sga research development rd acquired inprocess research development iprd nm nm incomeexpense net nm nm special acquisitionrelated charges nm nm equity income nm nm meaningful percentage substantially sales cholesterol products included scheringploughs net sales results sales reflected equity income addition due virtual nature joint venture scheringplough incurs substantial selling general administrative expenses captured equity income included scheringploughs statements consolidated operations result scheringploughs gross margin ratios sga expenses rd expenses percentage net sales reflect benefit impact joint ventures operating results gross margin gross margin percent compared percent gross margin unfavorably impacted million purchase accounting adjustments included cost sales purchase accounting adjustments result amortization fair values certain assets acquired part obs acquisition gross margin compared benefited realized cost savings approximately million manufacturing streamlining nonrecurrence million charges associated aforementioned manufacturing streamlining actions favorable product mix despite negative impacts cost sales costs resulting scheringploughs actions streamline manufacturing operations gross margin increased percent percent improvement gross margin primarily due increased sales higher margin products process improvements within scheringploughs supply chain including cost savings manufacturing streamlining activities completed cost sales included charges totaling million associated scheringploughs actions streamline manufacturing operations offset savings approximately million result actions see note special acquisition related charges manufacturing streamlining item financial statements supplemental data additional information selling general administrative selling general administrative expenses sga increased percent billion compared included sga million obs addition increase sga reflects higher promotion spending ongoing investments emerging markets unfavorable impact foreign exchange sga increased percent billion compared reflecting ongoing investments emerging markets field support product launches well higher promotional spending table contents research development research development rd spending increased percent billion compared period included rd million obs also included rd upfront payments million mainly related certain licensing transactions increase rd spending versus also reflects higher spending clinical trials related activities investments build greater breadth capacity support continued expansion scheringploughs pipeline rd spending increased percent billion compared period increase due higher costs associated clinical trials well building greater breadth capacity support scheringploughs progressing pipeline generally changes rd spending reflect timing scheringploughs funding internal research efforts research collaborations various partners discover develop steady flow innovative products maximize scheringploughs chances successful development new products scheringplough began development excellence initiative build talent critical mass create uniform level excellence deliver highpriority programs within rd scheringplough began global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory processes certain aspects global clinical harmonization program implemented acquired inprocess research development acquired inprocess research development charge billion result obs acquisition represents immediate expense recognition fair value acquired research projects technological feasibility established alternative future use incomeexpense net scheringplough income net million compared million income net expense net million income net included net realized gains foreign currency options million related obs acquisition increase income net also reflected higher interest income due higher balances cash equivalents shortterm investments partially offset higher interest expense due issuance new debt special acquisition related charges manufacturing streamlining special acquisition related charges year ended december scheringplough incurred million special acquisitionrelated charges comprised million integrationrelated costs obs acquisition million severance charges part integration activities manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamlined global supply chain enhanced scheringploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new jersey total actions resulted elimination positions scheringplough expects actions yield annualized cost savings approximately million special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico table contents following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed charges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december severance accrued liability december special charge activities special charges incurred follows dollars millions litigation charges employee termination costs asset impairment charges litigation charges litigation reserves increased million increase resulted total reserve million massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters representing scheringploughs current estimate resolve matter august scheringplough announced reached agreement us attorneys office district massachusetts us department justice settle massachusetts investigation aggregate amount million plus interest settlement amount relates massachusetts investigation awp investigations litigation ongoing schering plough made payments totaling million related settlement employee termination costs employee termination costs consisted million associated voluntary early retirement program verp us million employee termination costs asset impairment charges year ended december scheringplough recognized asset impairment charges million related primarily consolidation scheringploughs us biotechnology organizations equity income sales merckscheringplough cholesterol joint venture totaled billion billion billion respectively sales growth due primarily higher market share market growth us continued expansion international markets sales growth due primarily increase market share table contents companies bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement company physician details set annual basis italy contractual amount included profit sharing calculation reimbursed us canada puerto rico amount equal companys physician details multiplied contractual fixed fee scheringplough reports amounts part equity income amounts represent reimbursement specific incremental identifiable costs schering ploughs detailing cholesterol products markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher costs joint venture companies contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally scheringplough merck certain conditions specified joint venture agreements merck scheringplough could entitled receive reimbursements future research development expenses million additional information regarding joint venture merck also included note equity income item financial statements supplementary data equity income merckscheringplough joint venture totaled billion billion million respectively increase equity income compared reflected higher market share us international sales growth increase equity income compared reflected continued strong sales vytorin zetia scheringplough recognized milestones merck million related certain european approvals vytorin ezetimibesimvastatin noted scheringplough incurs substantial selling general administrative costs reflected equity income instead included overall cost structure scheringplough provision income taxes tax expense million million million respectively tax provision included tax benefits million related amortization fair values certain assets acquired part obs acquisition income tax provision primarily relates foreign taxes tax provision includes benefit million related irs notice issued august resulted reduction previously accrued tax liability attributable repatriations american jobs creation act ajca tax provisions include benefit related us operating losses schering plough established valuation allowance net us deferred tax assets including benefit us operating losses management concluded likely benefit us net deferred tax assets realized december schering plough continues maintain valuation allowance us net deferred tax assets scheringplough expects report us net operating loss nol carryforward billion tax return year ended december us nol carryforward could materially reduced examination scheringploughs income tax returns internal revenue service irs scheringplough generated approximately million us losses including impact purchase accounting however due differences financial tax reporting scheringplough expects report minimal increase nol us tax return scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings table contents balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax matters litigation see note legal environmental regulatory matters item financial statements supplemental data additional information january december total amount unrecognized tax benefits million million respectively includes reductions deferred tax assets carrying full valuation allowance potential refund claims tax liabilities january december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease next twelvemonth period million decrease would primarily attributable decision tax matter currently litigated newark district court possible final resolution scheringploughs examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment andor receipt related cash dependent number factors many outside scheringploughs control scheringplough includes interest expense income well potential penalties related tax positions component income tax expense statement consolidated operations total amount accrued interest related tax positions january december million million respectively included accrued liabilities second quarter irs completed examination scheringploughs federal income tax returns schering plough seeking resolution issue raised examination irs administrative appeals process scheringplough remains open irs tax years significant tax jurisdictions us state foreign scheringploughs income tax returns open examination period net lossincome available common shareholders scheringplough net lossincome available common shareholders billion billion million respectively net loss available common shareholders included approximately billion charges related purchase accounting obs acquisition including billion acquired inprocess research development charge net loss available common shareholders included deduction preferred stock dividends million related preferred stock net income available common shareholders included deduction preferred stock dividends million period related preferred stock net lossincome available common shareholders also included special acquisition related charges manufacturing streamlining costs approximately million million million respectively see note special acquisition related charges manufacturing streamlining item financial statements supplementary data additional information liquidity financial resources discussion cash flow fo r ye ars end e december dollars millions cash flow operating activities cash flow investing activities cash flow financing activities table contents operating activities operating activities provided billion cash compared net cash provided operations billion increase primarily due net realized gain million foreign currency options relating obs acquisition higher net sales equity income partially offset payments million settlement massachusetts investigation million tax interest due connection examination irs scheringploughs federal income tax returns part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options derivatives aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives shortterm trading nature hedge specific financing investment transaction accordingly cash impacts derivatives classified operating cash flows statement consolidated cash flows net cash provided operating activities billion increase billion compared increase primarily resulted higher net income timing operating cash payments receipts operating activities generated million cash including payments approximately million tax authorities tax liabilities related repatriation foreign earnings ajca tax payments million related settlement certain tax contingencies tax years investing activities net cash used investing activities billion primarily consisting billion net cash used purchase obs addition source cash investing activities included net reduction shortterm investments billion partially offset million capital expenditures net cash used investing activities billion primarily related net purchases shortterm investments billion previously invested cash equivalents million capital expenditures net cash used investing activities million primarily related million capital expenditures purchase intangible assets million partially offset proceeds sales property equipment million net reduction shortterm investments million financing activities net cash provided financing activities billion compared cash used billion period net cash provided financing activities included net proceeds issuance common mandatory convertible preferred shares approximately billion billion respectively net proceeds approximately billion issuance longterm debt net cash provided financing activities also included million proceeds stock option exercises offset payment dividends common preferred shares million net cash used financing activities billion million respectively uses cash financing activities include payment dividends common preferred shares million million respectively repayment billion bank debt shortterm commercial paper borrowings billion shortterm commercial paper borrowings uses cash financing activities partially offset proceeds million bank debt incurred foreign subsidiary related funding portion repatriations ajca bank debt fully repaid table contents discussion cash flows scheringplough moving forward additional investments enhance infrastructure business currently process building us pharmaceutical sciences center new jersey capital expenditures approximately million million made respectively related center additional capital expenditures approximately million expected next two years center allow scheringplough streamline integrate drug development process products moved drug discovery pipeline market additional related expenditures upgrade equipment staffing center december scheringplough net debt total debt less cash cash equivalents shortterm investments marketable securities billion cash generated operations available cash shortterm investments available credit facilities expected provide scheringplough ability fund cash needs intermediate term borrowings credit facilities september scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering approximately billion interest notes payable semiannually effective interest rate percent senior unsecured notes percent senior unsecured notes incorporates initial discount debt issuance fees percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted redemption date semiannual basis using rate treasury notes comparable remaining terms plus basis points notes basis points notes change control triggering event occurs defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase october scheringplough issued euro million aggregate principal amount percent senior unsecured euro denominated notes due euro billion aggregate principal amount percent senior unsecured eurodenominated notes due net proceeds offering approximately billion interest notes payable annually effective interest rate percent senior unsecured eurodenominated notes percent senior unsecured eurodenominated notes incorporates initial discount debt issuance fees impact interest rate hedges percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price specified prospectus change control triggering event occurs defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase scheringplough used net proceeds notes fund portion purchase price obs acquisition october scheringplough entered fiveyear senior unsecured eurodenominated term loan facility syndicate banks october scheringplough drew euro billion billion term loan fund portion purchase price obs acquisition new term table contents loan floating interest rate requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing term loan term loan also generally restricts schering plough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets reported us dollar amounts outstanding debt balance interest expense eurodenominated notes euro denominated term loan fluctuate due impact foreign currency translation november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due interest rates payable notes subject adjustment connection ratings downgrades december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply notes subsequently rated baa moodys bbb sp rating assigned notes either moodys sp downgraded respectively interest rate payable series notes would increase see note borrowings commitments item financial statements supplementary data additional information august scheringplough entered billion revolving credit agreement syndicate banks terminated billion credit facility due mature may credit facility floating interest rate matures august requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing credit facility credit facility also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets credit line available general corporate purposes considered support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december borrowings outstanding facility december shortterm borrowings including credit facilities mentioned totaled million million respectively including outstanding commercial paper million dates weightedaverage interest rate short term borrowings december percent percent respectively scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency translation sfas foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income table contents credit ratings scheringploughs current unsecured senior credit ratings outlook follows longterm senior unsecured credit ratings longterm shortterm review status moodys investors service baa p stable standard poors stable fitch ratings bbb f stable shortterm ratings discussed significantly affected scheringploughs ability issue rollover outstanding commercial paper borrowings time however scheringplough believes ability commercial paper issuers scheringplough one shortterm credit ratings p moodys sp andor f fitch issue rollover outstanding commercial paper times less companies higher shortterm credit ratings addition total amount commercial paper capacity available issuers typically less higherrated companies scheringploughs sizable lines credit commercial banks well cash shortterm investments held us international subsidiaries serve alternative sources liquidity support commercial paper program scheringploughs credit ratings could decline current levels impact decline could reduce availability commercial paper borrowing would increase interest rate portion scheringploughs short longterm debt discussed scheringplough believes existing cash shortterm investments available credit facilities cash generated operations allow scheringplough fund cash needs intermediate term mandatory convertible preferred stock august scheringplough issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale preferred stock fund portion purchase price obs acquisition share preferred stock automatically convert common shares scheringplough depending average closing price scheringploughs common shares trading day period ending third trading day prior mandatory conversion date august defined prospectus preferred shareholders may elect convert time prior august minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price scheringploughs common shares exceeds least trading days within period consecutive trading days scheringplough may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares share preferred stock preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent scheringplough legally permitted pay dividends board directors declares dividend payable scheringplough pay dividends dividend payment date dividend payment dates february may august november year first dividend paid november year ended december shares percent mandatory convertible preferred stock issued august preferred stock converted shares scheringplough common stock table contents equity issuance treasury shares august scheringplough issued common shares treasury shares per share net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale common shares fund portion purchase price obs acquisition see note acquisition item financial statements supplementary data contractual obligations offbalance sheet arrangements scheringplough various contractual obligations reported liabilities consolidated balance sheets others required recognized liabilities certain purchase commitments executory contracts following table summarizes payments due period scheringploughs known contractual obligations december p ment due period less total year years years years dollars millions shortterm borrowings current portion longterm debt longterm debt obligations operating lease obligations purchase obligations deferred compensation plan obligations obligations total longterm debt obligations include aggregate principal amount longterm debt excludes interest obligations see note borrowings commitments item financial statements supplementary data additional information purchase obligations include advertising research contracts capital expenditure commitments inventory expense items unless material research milestone payments likely paid include potential milestone payments since payments contingent occurrence certain events table also excludes research contracts cancelable scheringplough without penalty purchase obligations consist cancelable noncancelable items caption includes obligations based undiscounted amounts estimated payments certain scheringploughs pension plans preferred stock dividends managements estimate current portion unrecognized tax benefits contractual obligations regulatory competitive environment scheringplough operates scheringplough subject jurisdiction various national state local regulatory agencies regulations described detail part item business k regulatory compliance complex regulatory standards including good clinical practices good laboratory practices good manufacturing practices vary jurisdiction constantly evolving regulatory compliance also costly regulatory compliance also impacts timing needed bring new drugs market market drugs new indications failure comply regulations result delays approval drugs seizure recall drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions table contents regulatory compliance cost compliance failures material impact scheringploughs results operations cash flows financial condition much still unknown science human health every drug benefits risks societal government pressures constantly shifting demand innovation meet urgent unmet medical needs adversity risk pressures impact regulatory environment market scheringploughs products regulatory compliance pharmacovigilance consent decree august scheringplough announced dissolution consent decree us district court district new jersey see note consent decree item financial statements regulatory inspections scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert drugs manufacturer governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european medicines agency emea cited serious deficiencies reporting processes scheringplough continued work long term action plan rectify deficiencies provided regular updates emea fourth quarter local uk emea regulatory authorities conducted follow inspection assess scheringploughs implementation action plan first quarter authorities also inspected usbased components scheringploughs pharmacovigilance system inspectors acknowledged progress made since also continued note significant concerns quality systems supporting scheringploughs pharmacovigilance processes similarly follow inspection schering ploughs clinical trial practices uk inspectors identified issues respect scheringploughs management clinical trials related pharmacovigilance practices february scheringplough began global clinical harmonization program building clinical excellence trial design execution tracking strengthen scheringploughs scientific compliance rigor global basis certain aspects global clinical harmonization program implemented work expected continue several years addition fourth quarter local uk regulatory authority conducted followup inspection confirmed corrective actions committed scheringplough following inspection scheringploughs ukbased clinical trial operations fact completed early january local uk regulatory authority returned followup inspection scheringploughs uk pharmacovigilance operations inspection likewise confirmed number corrective actions completed since last inspection noted number actions scheringplough taken set forth scheringploughs periodic updates emea noted limited number observations scheringplough addressing scheringplough intends continue upgrading skills processes systems clinical practices pharmacovigilance scheringplough remains committed accomplish work invest significant resources area scheringplough know action emea national authorities take response inspections possible actions include inspections demands improvements reporting systems criminal sanctions schering plough andor responsible individuals changes conditions marketing authorizations scheringploughs products table contents regulatory compliance postmarketing surveillance scheringplough engages clinical trial research many countries around world clinical trial research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities failure comply current good clinical practices applicable laws regulations result delays approval clinical trials suspension ongoing clinical trials delays approval marketing authorizations criminal sanctions scheringplough andor responsible individuals changes conditions marketing authorizations scheringploughs products clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products addition situations raised concerns among prescribers patients relating safety efficacy pharmaceutical products general past several years occurrences increased recently media mischaracterization early topline results enhance clinical trail led concerns among patients prescribers zetia vytorin see discussion early developments executive summary management discussion analysis financial condition results operations scheringploughs personnel regular open dialogue fda regulators review product labels materials regular basis new information becomes known following wave recent product withdrawals companies significant safety issues health authorities fda emea pmda continued increase focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications reviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially us advertising promotion particular directtoconsumer advertising similarly major health authorities including fda emea pmda also increased collaboration amongst especially regard evaluation safety benefitrisk information media attention also increased current environment health authority regulatory action one market safety labeling change may regulatory prescribing marketing implications markets extent previously seen health authorities pmda japan publicly acknowledged significant backlog workload due resource constraints within agency backlog caused long regulatory review times new indications products added uncertainty predicting approval timelines markets pmda committed correcting backlog made progress last year expected continue foreseeable future uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect scheringploughs operations effect regulatory approval processes operations predicted scheringplough nevertheless achieved significant number important regulatory approvals since including approvals vytorin noxafil clarinex clarinex reditabs clarinex suboxone new indications temodar nasonex significant approvals since include asmanex dpi dry powder inhalation us pegintron zetia temodar esmeroneslax japan new indications remicade scheringplough also number significant regulatory submissions filed major markets awaiting approval pricing pressures described specifically note legal environmental regulatory matters item financial statements pricing sales marketing programs arrangements related business table contents practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs scheringplough also predict whether investigations affect marketing practices sales result could material adverse impact scheringploughs results operations cash flows financial condition business us many scheringploughs pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts us market scheringplough pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulting increased use generics increased purchasing power negotiating behalf medicare recipients international markets scheringplough operates environment government mandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs since scheringplough unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals us effect operations cash flows reasonably estimated similarly effect operations cash flows decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated competition market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted outlook scheringplough provide numeric guidance however following outlook may helpful readers assessing future prospects see earlier discussion matters relating merckscheringplough cholesterol joint ventures enhance clinical trial ims prescription data us shows date prescriptions vytorin zetia declined although prescription data shown early signs stabilization limitations prescription data early discern trends data likely weekly fluctuations ims reported prescription volumes vytorin zetia table contents trend identified wholesalers retail chains trade buyers may respond fluctuations changing buying patterns reducing inventory levels early determine business financial impact lower prescription volumes longerterm however first quarter merckscheringplough cholesterol joint venture sales vytorin zetia us likely negatively impacted scheringplough accounts joint venture equity method scheringplough successful advancing several research development projects late stage projects require sizable resources complete research development expenses expected continue increase next several years result expanded pipeline pipeline projects added obs acquisition need larger frequent longer clinical trials current global regulatory environment risks described item risk factors could cause actual results differ materially expectations provided section impact recently issued accounting standards september fasb issued sfas fair value measurements standard defines fair value establishes framework measuring fair value accordance generally accepted accounting principles expands disclosures fair value measurements standard codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions calendar year companies standard effective beginning january except nonfinancial items measured nonrecurring basis effective beginning january based scheringploughs current financial position impact standard consolidated financial statements expected material november fasb issued emerging issues task force issue eitf accounting deferred compensation postretirement benefits aspects collateral assignment splitdollar life insurance arrangements effective calendar year companies january task force concluded employer recognize liability postretirement benefit related collateral assignment splitdollar life insurance arrangement accordance either fasb statement apb opinion based substantive agreement employee task force also concluded employer recognize measure asset based nature substance collateral assignment splitdollar life insurance arrangement impact standard consolidated financial statements expected material february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement sfas permits entities choose measure many financial instruments certain items fair value sfas also includes amendment sfas accounting certain investments debt equity securities applies entities availableforsale trading securities statement effective beginning entitys first fiscal year begins november based scheringploughs current financial position impact standard consolidated financial statements expected material june fasb issued eitf issue accounting nonrefundable advance payments goods services received use future research development activities effective calendar year companies january task force concluded nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods table contents delivered services performed goods services longer expected provided impact standard consolidated financial statements expected material december fasb issued eitf issue accounting collaborative arrangements effective calendar year companies january task force clarified manner costs revenues sharing payments made received partner collaborative arrangements presented income statement set forth certain disclosures required partners financial statements scheringplough currently assessing potential impacts implementing standard december securities exchange commission sec issued staff accounting bulletin sab permits entities certain circumstances continue use simplified method estimating expected term plain vanilla options discussed sab accordance sfas revised sharebased payment guidance release effective january impact standard consolidated financial statements expected material december fasb issued sfas revised business combinations calendar year companies standard applicable new business combinations occurring january sfas r requires acquiring entity recognize assets acquired liabilities assumed transaction acquisitiondate fair value limited exceptions significantly sfas r require acquisition costs generally expensed incurred certain acquired contingent liabilities recorded fair value acquired inprocess research development recorded fair value indefinitelived intangible asset acquisition date standard also impact certain unresolved matters related purchase transactions consummated prior effective date standard scheringplough currently assessing potential impacts implementing standard december fasb also issued sfas noncontrolling interests consolidated financial statements amendment arb effective fiscal years interim periods within fiscal years beginning december standard establishes new accounting reporting standards noncontrolling interest subsidiary deconsolidation subsidiary scheringplough currently assessing potential impacts implementing standard critical accounting policies estimates following accounting policies estimates considered significant changes certain judgments assumptions inherent policies could affect scheringploughs financial statements revenue recognition rebates discounts returns provision income taxes acquisitions impairment goodwill intangible assets property accounting pensions postretirement benefit plans accounting legal regulatory matters revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers table contents scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process revenue recognition new products based specific facts circumstances including estimated acceptance rates established products similar marketing characteristics absent ability make reliable estimates rebates discounts returns scheringplough would defer revenue recognition product discounts granted based terms arrangements wholesalers managedcare organizations government purchasers certain market conditions rebates estimated based sales contract terms historical experience trend analysis projected market conditions various markets served scheringplough evaluates market conditions products groups products primarily analysis third party demand market research data well internally generated information data information provided purchasers obtained third parties subject inherent limitations accuracy validity sales returns estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition including expected generic introductions marketing matters specifically investigated analyzed part formulation return reserves scheringploughs agreements major us pharmaceutical wholesalers address number commercial issues product returns timing payment processing chargebacks quantity inventory held wholesalers respect quantity inventory held wholesalers agreements provide financial disincentive wholesalers acquire quantities product excess necessary meet current patient demand use agreements scheringplough expects avoid situations scheringploughs shipments product reflective current demand rebates discounts returns scheringploughs rebate accruals federal state governmental programs including medicaid medicare part december million million respectively commercial discounts returns rebate accruals december million million respectively accruals established period related revenue recognized resulting reduction sales establishment liabilities included total current liabilities case returns receivable adjustments allowance provided accounts receivable case governmental rebate programs scheringploughs payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy schering ploughs obligations additional information governmental inquiries focused part calculation rebates contained note legal environmental regulatory matters item financial statements supplementary data addition possible result governmental challenges changes interpretive guidance actual rebates could materially exceed amounts accrued table contents following summarizes activity accounts related accrued rebates sales returns discounts ear ended ear ended december december dollars millions accrued rebatesreturnsdiscounts beginning period obs accruals acquired november provision rebates adjustment prioryear estimates payments provision returns adjustment prioryear estimates returns provision discounts adjustment prioryear estimates discounts granted accrued rebatesreturnsdiscounts end period year ended december adjustment prioryear estimates rebates includes million related reversal previously accrued rebate amounts recorded us governments tricare retail pharmacy program us federal court ruled pharmaceutical manufacturers obligated pay formulating recording accruals management utilizes assumptions estimates include historical experience wholesaler data projection market conditions estimated lag time sale payment rebate utilization estimates forecasted product demand amounts discussed critical accounting policy entitled revenue recognition part review accruals management performs sensitivity analysis considers differing assumptions subject judgment rebate accrual calculation based upon scheringploughs sensitivity analysis reasonably possible changes assumptions related rebate accruals could favorably unfavorably impact net sales income taxes amount consistent provision income taxes scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax matters litigation see note legal environmental regulatory matters january december total amount unrecognized tax benefits million million respectively includes reductions deferred tax assets carrying full valuation allowance potential refund claims tax liabilities january december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease table contents next twelvemonth period million decrease would primarily attributable decision tax matter currently litigated newark district court possible final resolution taxpayers examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment andor receipt related cash dependent number factors many outside scheringploughs control scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations total amount accrued interest related uncertain tax positions january december million million respectively included accrued liabilities scheringplough records valuation allowance reduce deferred tax assets amount likely realized scheringplough considered ongoing prudent feasible tax planning strategies assessing need valuation allowance event scheringplough determine would able realize additional portion net deferred tax assets adjustment valuation allowance would increase income period determination made likewise scheringplough subsequently determine would able realize additional portion remaining net deferred tax asset future adjustment deferred tax asset would charged income period determination made acquisitions impairment goodwill intangible assets property scheringplough accounts acquired businesses using purchase method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values consolidated financial statements results operations reflect acquired business completion acquisition cost acquire business including transaction costs allocated underlying net assets acquired business based respective fair values excess purchase price estimated fair values net assets acquired recorded goodwill amounts allocated acquired inprocess research development expensed date acquisition intangible assets amortized based sales expected life asset judgments made determining estimated fair value assigned class assets acquired liabilities assumed well asset lives materially impact results operations useful lives determined based expected future period benefit asset considers various characteristics asset including projected cash flows intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled billion december intangible assets goodwill increased significantly due acquisition obs annual amortization expense next five years estimated approximately million per year based intangible assets recorded december value assets subject continuing scientific medical marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment certain scheringploughs manufacturing sites operate capacity overall costs operating manufacturing sites significantly increased due consent decree compliance activities scheringploughs manufacturing cost base relatively fixed actions part management significantly reduce scheringploughs manufacturing infrastructure involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements management continues review carrying value certain manufacturing assets indications impairment future events decisions may lead additional asset impairments andor related costs table contents accounting pension postretirement benefit plans pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions scheringplough assesses pension postretirement benefit plan assumptions regular basis evaluating assumptions scheringplough considers many factors including evaluation discount rate expected rate return plan assets healthcare cost trend rate retirement age assumption scheringploughs historical assumptions compared actual results analysis current market conditions asset allocations see note retirement plans postretirement benefits item financial statements supplementary data additional information discount rates used pension postretirement benefit plan calculations evaluated annually modified reflect prevailing market rates measurement date highquality fixed income debt instrument portfolio would provide future cash flows needed pay benefits included benefit obligations come due countries debt instruments thinly traded estimates based available market rates actuarial assumptions based upon managements best estimates judgment assumptions held constant increase basis points discount rate would estimated favorable impact million net pension postretirement benefit cost increase basis points expected rate return assumption would estimated favorable impact million net pension postretirement benefit cost assumptions held constant decrease basis points discount rate would estimated unfavorable impact million net pension postretirement benefit cost decrease basis points expected rate return assumption would estimated unfavorable impact million net pension postretirement benefit cost sensitivities based estimated net pension postretirement benefit cost includes annual impact obs plans expected rates return pension postretirement benefit plans represent average rates return earned plan assets period benefits included benefit obligation paid developing expected rate return scheringplough determines expected returns major asset classes principally equities fixed income real estate return expectations asset classes based assumptions economic growth inflation supported longterm historical data well scheringploughs actual experience return plan assets expected portfolio performance also reflects contribution active management appropriate unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based primarily calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ scheringploughs expected returns majority assets realized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees targeted investment portfolio scheringploughs us retirement plan allocated percent equities percent fixed income investments percent real estate targeted investment portfolio scheringploughs us postretirement benefit plan allocated percent equities percent fixed income investments portfolios equity weightings consistent longterm nature plans benefit obligations nonus pension plans targeted investment portfolio varies based duration pension liabilities local governmental rules regulations substantially investments equities fixed income valued based quoted public market values investments real estate valued based periodic appraisals september fasb issued sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december scheringplough accounts retirement postretirement benefit plans accordance sfas shareholders equity december reduced table contents approximately percent upon adoption sfas see note retirement plans postretirement benefits item financial statements supplemental data additional information sfas allows extended adoption date requirement scheringploughs yearend date measurement date defined benefit pension postretirement plans plans measurement dates yearend prior adoption sfas scheringplough adopted yearend measurement date effective impact consolidated financial statements related measurement date change material accounting legal regulatory matters management judgments estimates required accounting legal regulatory matters ongoing basis including insurance coverages scheringplough reviews status claims investigations legal proceedings ongoing basis time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs results operations cash flows financial condition market risk disclosure scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk scheringplough subsidiaries countries sales outside us accounted approximately percent global sales virtually sales denominated currencies local country scheringploughs reported profits cash flows exposed changing exchange rates date management deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact scheringploughs international operations widespread addition point time scheringploughs international subsidiaries hold financial assets liabilities denominated currencies us dollars financial assets liabilities consist primarily shortterm thirdparty intercompany receivables payables changes exchange rates affect translated value financial assets liabilities gains losses arise translation affect net income occasion scheringplough used derivatives hedge specific foreign currency exposures part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options mitigate exposure event significant strengthening euro compared us dollar scheringplough purchased options aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accounting derivative instruments hedging activities amended sfas accordingly gain derivatives recognized statement consolidated operations december open foreign currency option contracts scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income table contents interest rate equity price risk financial assets exposed changes interest rates andor equity prices primarily cash equivalents shortterm investments debt equity securities held qualified nonqualified trusts employee benefits assets totaled billion december cash equivalents shortterm investments percent decrease interest rates would decrease interest income approximately million securities held qualified nonqualified trusts due longterm nature liabilities trust assets fund scheringploughs exposure market risk deemed low financial obligations exposed variability interest rates primarily shortterm borrowings longterm floatingrate euro denominated term loan scheringplough longterm fixed rate debt outstanding percent decrease interest rates would increase fair value debt approximately million scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments item financial statements supplementary data portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt december open interest rate swaps disclosure notice cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time scheringplough may contain forwardlooking statements within meaning private securities litigation reform act forwardlooking statements relate strictly historical current facts based current expectations forecasts future events identify forwardlooking statements use words anticipate believe could estimate expect forecast project intend plan potential similar words terms particular forwardlooking statements include statements relating future actions ability access capital markets pending acquisitions prospective products product approvals timing conditions regulatory approvals patent intellectual property protection future performance effectiveness marketed products pipeline drugs trends performance including trends cholesterol market sales efforts research development programs anticipated spending estimates rebates discounts returns expenses programs reduce expenses outcome contingencies litigation investigations growth strategy expected synergies financial results forwardlooking statements publications may turn wrong guarantees schering ploughs financial operational performance performance scheringploughs stock scheringplough assume obligation update forwardlooking statement many factors could cause actual results differ scheringploughs forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known although possible predict identify factors scheringplough refers item risk factors report incorporate herein reference identification important factors respect risks uncertainties item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis financial condition results operations item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements report independent registered public accounting firm table contents scheringplough corporation subsidiaries statements consolidated operations amounts millions except per share figures f r ears en ed december net sales cost sales selling general administrative research development acquired inprocess research development incomeexpense net special acquisitionrelated charges equity income lossincome income taxes income tax expense net lossincome cumulative effect change accounting principle cumulative effect change accounting principle net tax net lossincome preferred stock dividends net lossincome available common shareholders diluted lossearnings per common share lossearnings available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax diluted lossearnings per common share basic lossearnings per common share lossearnings available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle basic lossearnings per common share dividends per common share accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows amounts millions fo r ears e n ded december operating activities net lossincome cumulative effect change accounting principle net tax net lossincome cumulative effect change accounting principle net tax adjustments reconcile net lossincome cumulative effect change accounting principle net tax net cash provided operating activities depreciation amortization accrued sharebased compensation special acquisition related charges payments purchases derivative currency options change fair value currency options proceeds derivative instruments acquired inprocess research development payment us taxing authorities changes assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities income taxes payable foreign currency transaction exchange loss net net cash provided operating activities investing activities capital expenditures dispositions property equipment acquisition net cash acquired purchases shortterm investments maturities shortterm investments net net cash used investing activities financing activities cash dividends paid common shareholders cash dividends paid preferred shareholders proceeds preferred stock issuance net proceeds common stock issuance net issuance longterm debt net shortterm borrowings payments shortterm borrowings stock option exercises net net cash provided byused financing activities effect exchange rates cash cash equivalents net decrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash paid interest net amounts capitalized cash paid income taxes see note accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets amounts millions except per share figures de ce mber assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt net current portion deferred income taxes longterm liabilities total longterm liabilities commitments contingent liabilities note shareholders equity mandatory convertible preferred shares par value per share face value issued december december mandatory convertible preferred shares par value per share face value issued december december common shares authorized shares par value issued december december paidin capital retained earnings accumulated comprehensive loss total less treasury shares cost total shareholders equity total liabilities shareholders equity accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity amounts millions ac cumulated mandatory mandatory total convertible convertible compre share preferred preferred common paidin retained treasury hensive holders shares shares shares capital earnings shares loss equity balance january comprehensive incomeloss net income foreign currency translation minimum pension liability net tax per sfas total comprehensive income cash dividends common shares dividends preferred shares stock incentive plans balance december comprehensive income net income foreign currency translation minimum pension liability net tax per sfas unrealized gain investments available sale net tax total comprehensive income cash dividends common shares dividends preferred shares accrued dividends common shares adjustment pension otherpostretirement liabilities upon adoption sfas net tax stock incentive plans balance december adoption fin comprehensive lossincome net loss foreign currency translation pension otherpostretirement liabilities net tax derivative interest rate instruments unrealized gain investments available sale net tax total comprehensive loss issuance preferred stock issuance common stock conversion preferred stock sfas measurement date provisions net tax cash dividends common shares dividends preferred shares accrued dividends common shares stock incentive plans balance december accompanying notes integral part consolidated financial statements table contents notes consolidated financial statements summary significant accounting policies overview scheringplough innovationdriven sciencecentered global health care company biopharmaceutical research collaborations partners scheringplough creates therapies help save improve lives around world scheringplough applies researchanddevelopment platform human prescription consumer products well animal health products november scheringplough acquired organon biosciences nv obs company discovers develops manufactures human prescription animal health products see note acquisitions additional information principles consolidation consolidated financial statements include scheringplough corporation subsidiaries scheringplough intercompany balances transactions eliminated accounts obs included part scheringploughs results date acquisition november use estimates preparation financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date financial statements reported amounts revenues expenses reporting period ongoing basis scheringplough evaluates estimates based historical experience various assumptions believed reasonable circumstances actual results could differ estimates equity method accounting scheringplough accounts share activity merckscheringplough joint venture joint venture merck co inc merck using equity method accounting scheringplough significant influence joint ventures operating financial policies accordingly scheringploughs net sales include sales joint venture scheringploughs share earnings joint venture included equity income determining consolidated net incomeloss equity income joint venture included human prescription pharmaceuticals segment revenue sales vytorin zetia recognized joint venture title risk loss passed customer equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck see note equity income additional information regarding joint venture cash cash equivalents cash cash equivalents include operating cash highly liquid investments original maturities three months less including highlyrated money market accounts shortterm investments shortterm investments carried fair value classified availableforsale investments consist certificates deposit commercial paper maturities less year table contents notes consolidated financial statements continued inventories inventories valued lower cost market cost determined using lastin firstout lifo method substantial portion inventories located us cost inventories determined firstin firstout method fifo depreciation property equipment depreciation provided estimated useful lives properties generally use straightline method useful lives new property acquisitions generally follows asset category ears buildings building improvements equipment scheringplough reviews carrying value property equipment indications impairment accordance statement financial accounting standard sfas accounting impairment disposal longlived assets depreciation expense million million million depreciation expense included accelerated depreciation related manufacturing streamlining million foreign currency translation net assets scheringploughs international subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included comprehensive incomeloss reflected separate component shareholders equity remaining international subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included statements consolidated operations exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation account transactional exchange gains losses included incomeexpense net revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business table contents notes consolidated financial statements continued recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process earnings per common share diluted earningsloss per common share computed dividing net incomeloss available common shareholders plus preferred stock dividends dilutive effect mandatory convertible preferred stock sum weighted average number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options dilutive effect shares issuable upon conversion scheringploughs mandatory convertible preferred stock basic earningsloss per common share computed dividing net incomeloss available common shareholders weighted average number common shares outstanding goodwill intangible assets financial accounting standards board fasb statement financial accounting standard sfas goodwill intangible assets requires intangible assets acquired either individually group assets initially recognized measured based fair value intangible finite life amortized useful life intangible indefinite life including goodwill amortized company assesses recoverability carrying value goodwill intangible assets indefinite useful lives annually whenever events changes circumstances indicate carrying amount asset may fully recoverable recoverability goodwill measured reporting unit level based twostep approach first carrying amount reporting unit compared fair value estimated future net discounted cash flows expected generated reporting unit extent carrying value reporting unit exceeds fair value reporting unit second step would performed wherein reporting units assets liabilities fair valued extent reporting units carrying value goodwill exceeds implied fair value goodwill impairment exists would recognized recoverability intangible assets indefinite useful lives measured comparison carrying amount intangible assets fair value respective intangible assets excess carrying value intangible assets fair value intangible assets would recognized impairment loss scheringplough conducts annual impairment testing goodwill october year based impairment tests performed impairment goodwill however assurance future goodwill indefinite lived assets impairment tests result charge statement consolidated operations scheringploughs goodwill intangible asset balances increased significantly due acquisition obs see note acquisition note goodwill intangible assets additional information assets included assets capitalized software million million december respectively amortization expense million million million respectively table contents notes consolidated financial statements continued income taxes scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january fin order recognize uncertain tax benefit taxpayer must likely sustaining position measurement benefit calculated largest amount percent likely realized upon resolution benefit deferred income taxes recognized future tax effects temporary differences financial income tax reporting basis scheringploughs assets liabilities based enacted tax laws rates accounting sharebased compensation prior january scheringplough accounted stockbased compensation arrangements using intrinsic value method sharebased employee compensation cost reflected statements consolidated operations scheringploughs deferred stock units performance plans stock options granted plans exercise price equal market value underlying common stock date grant effective january scheringplough accounts sharebased compensation accordance sfas revised sharebased payment sfas r see note sharebased compensation additional information shipping handling expenses shipping expenses classified selling general administrative expenses consolidated statement operations impact recently issued accounting pronouncements september fasb issued sfas fair value measurements standard defines fair value establishes framework measuring fair value accordance generally accepted accounting principles expands disclosures fair value measurements standard codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions calendar year companies standard effective beginning january except nonfinancial items measured nonrecurring basis effective beginning january based scheringploughs current financial position impact standard consolidated financial statements expected material november fasb issued emerging issues task force issue eitf accounting deferred compensation postretirement benefits aspects collateral assignment splitdollar life insurance arrangements effective calendar year companies january task force concluded employer recognize liability postretirement benefit related collateral assignment splitdollar life insurance arrangement accordance either fasb statement apb opinion based substantive agreement employee task force also concluded employer recognize measure asset based nature substance collateral assignment splitdollar life insurance arrangement impact standard consolidated financial statements expected material february fasb issued sfas fair value option financial assets financial liabilitiesincluding amendment fasb statement sfas permits entities choose measure many financial instruments certain items fair value sfas also table contents notes consolidated financial statements continued includes amendment sfas accounting certain investments debt equity securities applies entities availableforsale trading securities statement effective beginning entitys first fiscal year begins november based scheringploughs current financial position impact standard consolidated financial statements expected material june fasb issued eitf issue accounting nonrefundable advance payments goods services received use future research development activities effective calendar year companies january task force concluded nonrefundable advance payments goods services used rendered future research development activities deferred capitalized amounts recognized expense related goods delivered services performed goods services longer expected provided impact standard consolidated financial statements expected material december fasb issued eitf issue accounting collaborative arrangements effective calendar year companies january task force clarified manner costs revenues sharing payments made received partner collaborative arrangements presented income statement set forth certain disclosures required partners financial statements scheringplough currently assessing potential impacts implementing standard december securities exchange commission sec issued staff accounting bulletin sab permits entities certain circumstances continue use simplified method estimating expected term plain options discussed sab accordance sfas r guidance release effective january impact standard consolidated financial statements expected material december fasb issued sfas revised business combinations sfas r calendar year companies standard applicable new business combinations occurring january sfas r requires acquiring entity recognize assets acquired liabilities assumed transaction acquisitiondate fair value limited exceptions significantly sfas r require acquisition costs generally expensed incurred certain acquired contingent liabilities recorded fair value acquired inprocess research development recorded fair value indefinitelived intangible asset acquisition date standard also impact certain unresolved matters related purchase transactions consummated prior effective date standard scheringplough currently assessing potential impacts implementing standard december fasb also issued sfas noncontrolling interests consolidated financial statements amendment arb effective fiscal years interim periods within fiscal years beginning december standard establishes new accounting reporting standards noncontrolling interest subsidiary deconsolidation subsidiary scheringplough currently assessing potential impacts implementing standard acquisition scheringplough acquired obs purchase price approximately euro billion cash approximately billion including legal professional fees november acquisition date acquisition added diversification marketed products including two new therapeutic areas womens health central nervous system well significant strength animal health products rd pipeline purchase method accounting used account transaction accordance sfas business combinations operating results obs included scheringploughs consolidated financial statements period subsequent acquisition date table contents notes consolidated financial statements continued following table provides pro forma financial information years ended december acquisition occurred beginning period presented dollars millions except per share data unaudited net sales net loss cumulative effect change accounting principle net loss available common shareholders diluted loss per common share basic loss per common share pro forma financial information periods presented includes amortization stepup inventory billion acquired inprocess research development charge billion nonrecurring charges directly attributable accounting acquisition pro forma financial information also includes effect purchase accounting adjustments additional amortization expense acquired identifiable intangible assets depreciation stepup property effect given pro forma financial information synergistic benefits may realized costs related integration obs pro forma financial information considered indicative actual results would achieved acquisition consummated dates indicated purport indicate results operations future date future period preliminary allocation purchase price obs november follows ollars millions cash current assets excluding inventories inventories property identifiable intangible assets goodwill othernon current assets acquired inprocess research development iprd total assets acquired acquisition related liabilities current liabilities deferred tax liabilities othernon current liabilities total liabilities assumed net assets acquired allocation purchase price subject finalization scheringploughs management analysis fair value assets acquired including assets related pension plans liabilities assumed obs acquisition date final allocation purchase price may result additional adjustments recorded amounts assets liabilities may also result adjustments depreciation amortization acquired inprocess research development adjustments arising finalization purchase price allocation impact cash flows however adjustments could result material increases decreases net incomeloss available common shareholders revisions purchase price allocation made additional information becomes available final allocation expected completed soon practicable later months acquisition date table contents notes consolidated financial statements continued preliminary purchase price allocation identifiable intangible assets follows weighted average dollars millions amortization period years intangible assets determinable lives patents trademarks total intangible assets weighted average life billion total intangibles approximately years intangible assets significant residual value acquired intangible assets determined indefinite life billion goodwill assigned human prescription pharmaceuticals segment million assigned animal health segment none goodwill deductible income tax purposes preliminary value billion assigned acquired iprd charged operations fourth quarter charge associated research projects animal health research projects womens health central nervous system anesthesia therapeutic areas human health amount determined using discounted cash flow projections identified research projects technological feasibility established alternative future use discount rates used ranged percent percent projected launch dates following fda regulatory approval years time scheringplough expects projects begin generate cash flows cost complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated cost complete projects near final stages development excess million research development projects considered valuation subject normal risks uncertainties associated demonstrating safety efficacy required obtain fda regulatory approvals included acquisition related liabilities involuntary termination benefits costs exit certain activities obs conjunction obs acquisition scheringplough agreed divest certain assets part regulatory reviews us europe assets classified held sale included current assets consolidated balance sheet material special acquisition related charges manufacturing streamlining special acquisition related charges year ended december scheringplough incurred million special acquisitionrelated charges comprised million integrationrelated costs obs acquisition million severance charges part integration activities manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamlined global supply chain enhanced scheringploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new table contents notes consolidated financial statements continued jersey total actions resulted elimination positions actions yielded annualized cost savings approximately million special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed c harges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december severance accrued liability december special charge activities special charges incurred follows dollars millions litigation charges employee termination costs asset impairment charges litigation charges litigation reserves increased million increase resulted total reserve million massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters representing scheringploughs current estimate resolve matter august scheringplough announced reached agreement us attorneys office district table contents notes consolidated financial statements continued massachusetts us department justice settle massachusetts investigation aggregate amount million paid settlement amount relates massachusetts investigation awp investigations litigation ongoing employee termination costs employee termination costs consisted million associated voluntary early retirement program verp us million employee termination costs asset impairment charges year ended december scheringplough recognized asset impairment charges million related primarily consolidation scheringploughs us biotechnology organizations equity income may scheringplough merck co inc merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide scheringplough merck jointly develop commercialize ezetimibe cholesterol management field oncedaily monotherapy managed zetia us asia ezetrol europe ii coadministration various approved statin drugs iii fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin managed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched many international markets scheringplough utilizes equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringploughs net sales include sales joint venture cholesterol joint venture agreements provide sharing operating income generated joint venture based upon percentages vary product sales level country us market scheringplough receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough generally share profits equally scheringploughs allocation joint venture income increased milestones recognized either companys share joint ventures income operations subject reduction company fails perform specified minimum number physician details particular country companies agree annually minimum number physician details country companies bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement company physician details set annual basis italy contractual amount included profit sharing calculation reimbursed us canada puerto rico amount equal companys physician details multiplied contractual fixed fee scheringplough reports amounts part equity income cholesterol joint venture amounts represent reimbursement specific incremental identifiable costs schering table contents notes consolidated financial statements continued ploughs detailing cholesterol products markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher year ended december scheringplough recognized milestones million milestones related certain european approvals vytorin ezetimibesimvastatin costs joint venture companies contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally scheringplough merck certain conditions specified joint venture agreements merck scheringplough could entitled receive reimbursements future research development expenses million following information provides summary components scheringploughs equity income cholesterol joint venture year ended december dollars millions scheringploughs share net income including milestones contractual amounts physician details elimination intercompany profit net total equity income merckscheringplough joint venture equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck due virtual nature cholesterol joint venture scheringplough incurs substantial costs selling general administrative costs reflected equity income borne overall cost structure scheringplough costs reported respective line items statements consolidated operations separately identifiable cholesterol agreements provide jointly owned facilities products resulting joint venture manufactured facilities owned either scheringplough merck allergyasthma agreements provide joint development marketing companies oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis new drug application filing combination tablet accepted us food drug administration fda standard review scheringplough announced agreed merck commence development singletablet combination ezetimibe atorvastatin treatment elevated cholesterol levels see note legal environmental regulatory matters discussion enhance matter sharebased compensation prior january scheringplough accounted stock compensation arrangements using intrinsic value method followed recognition measurement principles apb opinion accounting stock issued employees related interpretations prior stockbased employee compensation cost reflected statement consolidated operations table contents notes consolidated financial statements continued scheringploughs deferred stock units stock options granted plans exercise price equal market value underlying common stock date grant scheringplough adopted sfas r effective january sfas r requires companies recognize compensation expense amount equal fair value sharebased payments granted employees scheringplough elected modified prospective transition method therefore adjustments prior periods required result adopting sfas r method provisions sfas r apply awards granted date adoption unrecognized expense awards unvested date adoption based grant date fair value sfas r also amended sfas statement cash flows require excess tax benefits reflected operating cash flows reflected financing cash flows grants issued retirementeligible employees prior adoption sfas r scheringplough recognized compensation costs stated vesting period stock option deferred stock unit acceleration unrecognized compensation costs upon retirement employee upon adoption sfas r scheringplough recognizes compensation costs sharebased grants made january service period earlier one year employee becomes retirement eligible first year grant ii employees retirement eligibility date first year grant iii service period award november financial accounting standards board fasb issued fasb staff position fas r transition election related accounting tax effects sharebased payment awards scheringplough elected adopt transition method provided fasb staff position purposes calculating pool excess tax benefits available absorb tax deficiencies recognized subsequent adoption sfas r stock incentive plan plan approved scheringploughs shareholders terms plan million scheringploughs authorized common shares may granted stock options awarded deferred stock units officers certain employees scheringplough december scheringplough intends utilize unissued authorized shares satisfy stock option exercises issuance deferred stock units expensed related sharebased compensation classified line item associated employees function scheringplough granted performancebased deferred stock units stock incentive plan provide certain senior managers opportunity earn shares scheringplough common stock units earned specific preestablished levels performance service achieved three year performance period implementation sfas r first quarter scheringplough recognized benefit income million cumulative effect change accounting principle related two longterm compensation plans required accounted liability plans sfas r tax benefits recognized related stockbased compensation related cash flow impacts material scheringplough us net operating loss position stock options stock options granted employees exercise prices equal fair market value scheringploughs stock dates grant stock options plan generally vest three years term seven years certain options granted previous plans vest longer periods ranging three nine years term years compensation costs stock options recognized table contents notes consolidated financial statements continued requisite service period separately vesting portion stock option award expense recognized net estimated forfeitures vesting period options using accelerated method expense recognized approximately million respectively weightedaverage assumptions used blackscholes optionpricing model follows dividend yield volatility riskfree interest rate expected term options years dividend yields based historical dividend yields expected volatilities based historical volatilities scheringploughs common stock expected differ materially future volatility riskfree interest rate based us treasury yield curve effect time grant periods corresponding expected life options expected term options represents weighted average period time options granted expected outstanding giving consideration vesting schedules schering plough utilizes simplified method calculating expected term stock options allowed sab amended sab amount cash received exercise stock options million million million respectively stockbased compensation prior january determined using intrinsic value method following table provides supplemental information stockbased compensation computed sfas dollars millions except per share figures net income available common shareholders reported add back expense included reported net income deferred stock units deduct pro forma expense stock options deferred stock units charged net income available common shareholders accordance sfas pro forma net income available common shareholders using fair value method diluted earnings per common share diluted earnings per common share reported pro forma diluted earnings per common share using fair value method basic earnings per common share basic earnings per common share reported pro forma basic earnings per common share using fair value method table contents notes consolidated financial statements continued summarized information stock options outstanding exercisable december follows ou tstanding exerc able weighted weighted weighted number average average number average remaining exercise exercise exercise price range options term years price options price thousands thousands weightedaverage fair value stock options granted respectively intrinsic value stock options exercised million million million respectively total fair value options vested million million million respectively december total remaining unrecognized compensation cost related nonvested stock options amounted million amortized weightedaverage remaining requisite service period years following table summarizes stock option activity december changes year ended current prior plans w eighted number average exercise options price thousands outstanding january granted exercised canceled expired outstanding december exercisable december aggregate intrinsic value stock options outstanding december million aggregate intrinsic value stock options currently exercisable december million intrinsic value stock options calculated based exercise price underlying awards quoted price scheringploughs common stock reporting date table contents notes consolidated financial statements continued following table summarizes nonvested stock option activity december changes year ended current prior plans w eighted number average fair options value thousands nonvested january granted vested forfeited nonvested december deferred stock units fair value deferred stock units determined based number shares granted quoted price scheringploughs common stock date grant deferred stock units generally vest end three years provided employee remains service scheringplough expense recognized straightline basis vesting period deferred stock units payable equivalent number common shares expense recognized million million million respectively summarized information deferred stock units outstanding december follows standing weighted number average weighted deferred stock remaining average deferred stock unit price range units term years fair value thousands weightedaverage fair value deferred stock units granted respectively total fair value deferred stock units vested million million million respectively december total remaining unrecognized compensation cost related deferred stock units amounted million amortized weightedaverage remaining requisite service period years table contents notes consolidated financial statements continued following table summarizes deferred stock unit activity december changes year ended current prior plans number nonvested weighted deferred stock average units fair value thousands nonvested january granted vested forfeited nonvested december performancebased deferred stock units distribution performancebased deferred stock units contingent scheringplough meeting either performance andor market conditions one half performancebased stock unit grant performance condition fair value units based closing stock price date grant half grant market condition fair value units determined using lattice valuation model expected volatility assumptions assumptions appropriate determining fair value weighted average grantdate fair value performancebased deferred stock units granted represented approximately underlying shares december none units vested compensation expense performancebased stock units based fair values awards expected vest based performance measures recognized performance period compensation expense recognized year ended million december unrecognized compensation cost related performancebased deferred stock units million amortized remaining weighted average requisite service period years remaining unrecognized compensation cost performancebased deferred stock units may vary reporting period based changes expected achievement performance measures liability plans scheringplough two compensation plans classified liability plans sfas r ultimate cash payout plans based scheringploughs stock performance compared stock performance peer group upon adoption sfas r january scheringplough recognized cumulative income effect change accounting principle million order recognize liability plans fair value service period income expense amounts related liability plans based change fair value reporting date fair value plans estimated using lattice valuation model using expected volatility assumptions assumptions appropriate determining fair value one liability plans service period concluded december value plan became fixed expense recognized liability plans statements consolidated operations exclusive impact cumulative effect change accounting principle million million respectively december total remaining unrecognized compensation cost related liability plans amounted million amortized weightedaverage remaining requisite service period year amount vary reporting period based changes fair value plan remaining service requirement table contents notes consolidated financial statements continued incomeexpense net components incomeexpense net follows dollars millions interest cost incurred less amount capitalized construction interest expense interest income foreign exchange gainslosses net realized gain foreign currency options net ineffective portion interest rate swaps net total incomeexpense net net foreign exchange gains million includes million foreign currency transaction exchange losses related euro denominated debt instruments prior accounted economic hedges net investment foreign operation currency exchange losses noncash items included adjustments reconcile net loss net cash provided operating activities statement consolidated cash flows part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options derivatives aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accounting derivative instruments hedging activities amended sfas accordingly gain derivatives recognized statement consolidated operations derivatives shortterm trading nature hedge specific financing investing transaction accordingly cash impacts derivatives classified operating cash flows statement consolidated cash flows scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest rate payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt cash flow impacts interest rate swaps classified operating cash flows statement consolidated cash flows scheringplough participated healthcare refinancing programs adopted local government fiscal authorities major european market year ended december scheringplough transferred million trade accounts receivables owned foreign subsidiaries thirdparty financial institutions without recourse year ended december scheringplough transferred million trade accounts receivables owned foreign subsidiary thirdparty financial institutions without recourse transfer trade accounts receivable qualified sales accounts receivable sfas accounting transfers servicing financial assets extinguishments liabilities years ended december transfer trade accounts receivable table contents notes consolidated financial statements continued material impact scheringploughs statement consolidated operations cash flows transactions included change accounts receivable operating activities income taxes components consolidated lossincome income taxes years ended december follows dollars millions united states foreign total lossincome income taxes including cumulative effect change accounting principle loss included acquired inprocess research development charge amortization fair values certain assets acquired part obs acquisition income cholesterol joint venture included table based jurisdiction income earned components income tax expense years ended december follows fe deral tate fo reign otal dollars millions current deferred total current deferred total current deferred total scheringplough established valuation allowance net us deferred tax assets including benefit us operating losses management concluded likely benefit us net deferred tax assets realized december scheringplough continues maintain valuation allowance us net deferred tax assets scheringplough repatriated approximately billion accordance planned repatriation provisions american jobs creation act ajca maximum amount foreign earnings qualified effectively reduced tax rate percent tax provision related ajca recorded scheringploughs tax provision year ended december includes us federal income tax benefit approximately million result irs notice issued august provisions notice resulted reduction previously accrued tax liability attributable ajca repatriation also reduced us net operating loss nol carried forward subsequent years table contents notes consolidated financial statements continued prior ajca scheringploughs intent indefinitely reinvest unremitted earnings international subsidiaries except amounts repatriated ajca scheringplough maintains intent indefinitely reinvest earnings international subsidiaries scheringplough provided deferred taxes approximately billion undistributed foreign earnings december determining tax liability would arise earnings remitted practicable liability would depend number factors including amount earnings distributed whether us operations generating taxable profits losses deferred income taxes provided temporary differences financial reporting basis tax basis scheringploughs assets liabilities scheringploughs deferred tax assets result principally recording certain items currently deductible tax purposes net operating loss tax credit carryforwards scheringploughs deferred tax liabilities principally result book tax basis difference resulting obs acquisition use accelerated depreciation tax purposes components scheringploughs deferred tax assets liabilities december follows dollars millions deferred tax assets nol carryforwards tax credit carryforwards postretirement employee benefits inventory related sales return reserves litigation accruals intangible assets total deferred tax assets deferred tax liabilities depreciation inventory valuation obs intangible assets total deferred tax liabilities deferred tax valuation allowance net deferred tax liabilitiesassets change valuation allowance principally related increase deferred tax liabilities related acquisition obs deferred tax assets net operating losses tax credit carryforwards principally relate us nols research development rd tax credits us foreign tax credits federal alternative minimum tax amt credit carryforwards december scheringplough approximately billion us nols income tax purposes available offset future us taxable income us nols us operating losses adjusted differences financial tax reporting us nols expire varying amounts unused state nols related us nols well incremental amount related obss state nols expire varying amounts december scheringplough approximately million rd tax credits table contents notes consolidated financial statements continued carryforwards expire million foreign tax credit carryforwards expire million amt tax credit carryforwards indefinite life us nol carryforward could materially reduced examination scheringploughs income tax returns internal revenue service irs scheringplough reduced deferred tax assets related valuation allowance recorded us nols tax credit carryforwards reflect estimated resolution examinations difference income taxes based us statutory tax rate scheringploughs income tax expense years ending december due following dollars millions income tax benefitexpense us statutory rate increasedecrease taxes resulting lower rates jurisdictions net federal benefit repatriated foreign earnings act net credits us operating losses tax benefit recorded permanent differences state income tax provision tax matters income tax effective tax rate permanent differences largely attributable acquired inprocess research development charge billion related acquisition obs tax benefit recorded lower tax rates jurisdictions net primarily attributable scheringploughs manufacturing subsidiaries singapore ireland puerto rico operate various incentive tax grants begin expire additionally major countries schering plough conducts operations statutory tax rates less us tax rate overall income taxes primarily relate foreign taxes include benefit related us operating losses scheringplough implemented provisions fasb interpretation accounting uncertainty income taxes fin january required fin cumulative effect applying provisions interpretation reported adjustment scheringploughs retained earnings balance january scheringplough reduced january retained earnings million result adoption fin scheringploughs unrecognized tax benefits result primarily varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property well scheringploughs tax matters litigation see note legal environmental regulatory matters january december total amount unrecognized tax benefits million million respectively includes reductions deferred tax assets carrying full valuation allowance potential refund claims tax liabilities january december approximately million million respectively total unrecognized tax benefits recognized would affect effective tax rate management believes reasonably possible total unrecognized tax benefits could decrease next twelvemonth period million would primarily attributable decision tax matter currently litigated newark district court possible final resolution scheringploughs examination irs appeals possible resolutions various matters however timing ultimate resolution scheringploughs tax matters payment receipt related cash dependent number factors many outside scheringploughs control table contents notes consolidated financial statements continued scheringplough includes interest expense income well potential penalties uncertain tax positions component income tax expense statement consolidated operations total amount accrued interest related uncertain tax positions january december million million respectively included accrued liabilities tabular reconciliation scheringploughs fin unrecognized tax benefits january december follows ollars millions january additions tax positions related additions tax positions related prior years additions tax positions related acquired entities reductions tax positions related prior years reductions potential refund claims reductions related amounts settled taxing authorities lapses statutes limitations december schering plough considering filing refund claims based court decisions involving claim right doctrine two recent courts appeal decision clarifying law area made clear schering plough would prevail claims amount unrecognized tax benefits reduced accordingly impact net loss net consolidated income tax payments exclusive payments related tax examinations litigation discussed million million million respectively january irs completed examination scheringploughs federal income tax returns scheringplough made cash payment third quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charges payment fully satisfied liability associated tax examination consistent previously recorded reserves second quarter irs completed examination scheringploughs federal income tax returns schering plough seeking resolution issue raised examination irs administrative appeals process scheringplough remains open irs tax years significant tax jurisdictions us state foreign scheringploughs income tax returns open examination period july scheringplough made payment million irs pertaining examination october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently tried newark district court scheringploughs tax reserves adequate cover abovementioned payments table contents notes consolidated financial statements continued retirement plans postretirement benefits plan descriptions scheringplough defined benefit pension plans covering eligible employees us certain foreign countries largest us plan scheringplough retirement plan benefits normal retirement primarily based upon participants average final earnings years service social security income modified early retirement death disability benefits also available plan benefits become fully vested five years service plan provides continued accrual credited service employees opt postpone retirement remain employed scheringplough reaching normal retirement age nonus pension plans offer benefits competitive local market conditions defined benefit plans assumed scheringplough part obs acquisition included scheringploughs results operations acquisition date financial position december see note acquisition addition scheringplough provides postretirement medical life insurance benefits primarily eligible us retirees dependents postretirement benefit plans effective december scheringplough accounts retirement plans postretirement benefit plans plans accordance sfas employers accounting defined benefit pension postretirement plans sfas amendment sfas r sfas requires recognition asset overfunded plans liability underfunded plans scheringploughs consolidated balance sheets statement also requires recognition changes funded status plans year changes occur sfas allows extended adoption date requirement scheringploughs yearend date measurement date defined benefit pension postretirement plans plans measurement dates yearend prior adoption sfas scheringplough adopted yearend measurement date effective impact consolidated financial statements related measurement date change material incremental effects resulting implementation sfas individual line items scheringploughs consolidated balance sheets december follows balance sheets balance sheets amounts prior amounts sfas sfas sfas sfas adjustments adjustments adjustments adjustments dollars millions assets intangible assets longterm assets including deferred tax asset liabilities accrued compensation longterm liabilities equity accumulated comprehensive loss net tax effects included scheringploughs accumulated comprehensive loss december million million net tax effects million million net tax effects respectively costs recognized components net periodic benefit costs pursuant table contents notes consolidated financial statements continued sfas employers accounting pensions sfas employers accounting postretirement benefits pensions components costs december follows oth e r post retirement plans retirement benefits dollars millions actuarial loss prior service costcredit total actuarial losses primarily represent cumulative difference actuarial assumptions actual returns plan assets changes discount rates plans experience total loss amounts net excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amounts accumulated comprehensive loss expected recognized components net periodic costs follows retirement postretirement plans benefits dollars millions actuarial loss recognition prior service costcredit recognition actuarial assumptions consolidated weighted average assumptions used determine benefit obligations december oth e r pos retirement retirement plans benefits discount rate rate increase future compensation na na assumptions used develop benefit obligations yearend consolidated weighted average assumptions used determine net benefit costs years ended december oth e r pos tret ir emen retirement plans benefits discount rate longterm expected rate return plan assets rate increase future compensation na na na assumptions used determine net periodic benefit costs year established end previous year assumptions used determine benefit obligations established yearend net periodic benefit costs actuarial present value benefit obligations based actuarial assumptions determined annually based evaluation longterm trends well market conditions may impact cost providing retirement benefits longterm expected rates return plan assets derived return assumptions determined major asset classes equities fixed income real estate proportional basis return table contents notes consolidated financial statements continued expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weighted average assumed healthcare cost trend rate used postretirement measurement purposes percent trending percent one percent increase assumed healthcare cost trend rate would increase combined post retirement service interest cost million postretirement benefit obligation million one percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assumed based annual rates retirement experienced scheringplough components net periodic benefit costs net pension postretirement benefit costs totaled million million million respectively components net pension postretirement benefits expense follows ot h er pos tre remen retirement plans benefits dollars millions service cost interest cost expected return plan assets amortization net termination benefits settlements net pension postretirement benefit costs table contents notes consolidated financial statements continued benefit obligations components changes benefit obligations follows ther postretirement retirement plans benefits dollars millions benefit obligations beginning year service cost interest cost medicare drug subsidy received participant contributions effects exchange rate changes benefits paid acquisitionsplan transfers actuarialgains losses including assumption change change measurement date plan amendments termination benefits curtailment settlement benefit obligations end year benefit obligations overfunded plans benefit obligations underfunded plans funded status balance sheet presentation components changes plan assets follows ther postretirement retirement plans benefits dollars millions fair value plan assets primarily stocks bonds beginning year actual gain plan assets employer contributions participant contributions acquisitionsplan transfers effects exchange rate changes settlements benefits paid fair value plan assets end year plan assets overfunded plans plan assets underfunded plans table contents notes consolidated financial statements continued increase benefit obligations retirement plan assets december primarily due acquisition andor plan transfers related scheringploughs acquisition obs november obs benefit obligations retirement plan assets based preliminary estimate fair value addition plan assets indicated december securities investments million million respectively held nonqualified trust designated provide pension benefits certain underfunded plans accordance sfas december net asset overfunded plans million million respectively related scheringploughs retirement plans included longterm assets net liability underfunded plans december totaled billion billion respectively follows ther postretirement retirement plan benefits dollars millions accrued compensation current longterm liabilities total december accumulated benefit obligations abo retirement plans billion billion respectively aggregated accumulated benefit obligations fair values plan assets retirement plans accumulated benefit obligations excess plan assets billion billion respectively december billion billion respectively december plan assets fair value asset allocation consolidated retirement plans december target allocation follows per ce ntage target plan assets allocation december asset category equity securities debt securities real estate total asset allocation postretirement benefit trusts december target allocation follows per ce ntage target plan assets allocation december asset category equity securities debt securities total scheringploughs investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns table contents notes consolidated financial statements continued consistent acceptable level overall portfolio market value risk assets periodically rebalanced back target allocations estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid retirement postretirement plans benefits dollars millions years scheringploughs practice fund qualified pension plans least sufficient amounts meet minimum requirements set forth applicable laws scheringplough expects contribute approximately million retirement plans including minimum approximately million us scheringplough retirement plan defined contribution plans scheringplough maintains defined contribution savings plans us including plan acquired part obs acquisition largest us plan scheringplough makes contributions plan equal three percent eligible employee earnings plus matching contribution two percent eligible employee earnings based employee contributions total scheringplough contributions plan million million respectively scheringplough also maintains defined contribution retirement plans various jurisdictions scheringploughs contributions plans material earnings per common share following table reconciles components basic diluted earningsloss per share computations dollars shares millions eps numerator net lossincome available common shareholders eps denominator weighted average shares outstanding basic eps dilutive effect options deferred stock units average shares outstanding diluted eps third quarter scheringploughs mandatory convertible preferred stock converted million common shares common shares included weighted average shares calculation period conversion table contents notes consolidated financial statements continued years ended december million million million common shares respectively obtainable upon conversion mandatory convertible preferred stock excluded computation diluted lossearnings per common share effect would antidilutive weighted average basis period prior conversion addition year ended december approximately million common shares obtainable upon conversion mandatory convertible preferred stock excluded computation diluted lossearnings common per share effect would antidilutive equivalent common shares issuable scheringploughs stock incentive plans excluded computation diluted lossearnings per common share effect would antidilutive million million million respectively years ended december respectively scheringplough issued common shares august common shares included weightedaverage shares calculation period issuance see note shareholders equity additional information accumulated comprehensive loss components accumulated comprehensive loss december follows dollars millions foreign currency translation adjustment pension otherpostretirement liabilities net tax effects accordance sfas provisions accumulated derivative loss unrealized gain investments available sale net tax total see note retirement plans postretirement benefits additional information regarding impacts scheringploughs financial statements upon adoption sfas included foreign currency translation adjustment million charge comprehensive loss scheringploughs eurodenominated debt instruments designated effective economic hedges net investment foreign operation effective december scheringplough accounts retirement postretirement benefit plans accordance sfas implementation sfas resulted increase million net tax effects accumulated comprehensive loss reduced shareholders equity scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest rate payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt year ended december million effective portion interest rate swaps recognized interest expense million expected recognized interest expense table contents notes consolidated financial statements continued gross unrealized pretax gains investments million million respectively unrealized losses immaterial inventories inventories consisted following december dollars millions finished products goods process raw materials supplies total inventories inventory classified noncurrent assets included assets december million million respectively inventory expected sold within one year inventories valued lastin firstout lifo basis comprised approximately percent percent total inventories december respectively estimated replacement cost total inventories december billion billion respectively cost inventories determined firstin firstout method fifo goodwill intangible assets part purchase accounting acquisition obs scheringplough recorded billion goodwill billion assigned human prescription pharmaceuticals segment million assigned animal health segment none goodwill related obs acquisition deductible income tax purposes following table summarizes goodwill activity years ending december human human prescription animal prescription animal pharmaceuticals health total pharmaceuticals health total dollars millions goodwill balance january acquisitions foreign exchange writeoffs goodwill balance december table contents notes consolidated financial statements continued components intangible assets net follows december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net dollars millions patents trademarks licenses total intangible assets patents trademarks licenses amortized straightline method respective useful lives residual value intangible assets estimated zero part purchase accounting acquisition obs scheringplough recorded billion intangible assets see note acquisition additional information amortization expense related intangible assets million million million respectively included cost sales statement consolidated operations intangible assets reviewed determine recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review annual amortization expenses related intangible assets years expected approximately million product licenses august scheringplough exercised right develop commercialize centocor inc centocor golimumab new anti tnfalpha monoclonal antibody developed therapy treatment rheumatoid arthritis immunemediated inflammatory diseases pursuant exercise scheringplough received exclusive worldwide marketing rights golimumab excluding us japan china including hong kong taiwan indonesia exchange rights agreement scheringplough made upfront payment amount million centocor tax benefit million payment included research development expenses year ended december scheringplough sharing development costs centocor december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade golimumab extending scheringploughs rights exclusively market remicade match duration scheringploughs exclusive marketing rights golimumab effective upon regulatory approval golimumab eu scheringploughs marketing rights products extend years first commercial sale golimumab within eu centocor receive progressively increased share profits scheringploughs distribution products scheringplough marketing territory share profits remain fixed thereafter remainder term changes duration remicade marketing rights profit sharing arrangement products conditioned approval golimumab granted prior september scheringplough may independently develop market golimumab crohns disease indication territories option centocor participate addition scheringplough centocor agreed utilize autoinjector device commercialization golimumab agreed share development costs rights device scheringplough made upfront payment million included research development expenses year ended december effective september scheringplough restructured integrilin copromotion agreement millennium terms restructured agreement scheringplough acquired exclusive table contents notes consolidated financial statements continued us development commercialization rights integrilin exchange upfront payment million royalties integrilin sales scheringplough agreed pay minimum royalties million per year millennium scheringplough also purchased existing integrilin inventory millennium million upfront payment capitalized included intangible assets borrowings commitments short longterm borrowings scheringploughs outstanding borrowings december follows dollars millions shortterm commercial paper shortterm borrowings current portion longterm debts current portion capital leases total shortterm borrowings longterm senior unsecured eurodenominated notes due floating rate eurodenominated term loan due senior unsecured notes due senior unsecured eurodenominated notes due senior unsecured notes due senior unsecured notes due senior unsecured notes due capital leases longterm borrowings total longterm borrowings scheringploughs shortterm borrowings consist primarily bank loans commercial paper issued us weighted average interest rate shortterm borrowings percent percent december respectively senior unsecured notes october scheringplough issued euro million aggregate principal amount percent senior unsecured euro denominated notes due euro billion aggregate principal amount percent senior unsecured eurodenominated notes due net proceeds offering approximately billion interest notes payable annually effective interest rate percent senior unsecured eurodenominated notes percent senior unsecured eurodenominated notes incorporates initial discount debt issuance fees impact interest rate hedges percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price specified prospectus change control triggering event occurs defined prospectus holders notes right require scheringplough repurchase part notes cash table contents notes consolidated financial statements continued payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase september scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering approximately billion interest notes payable semiannually effective interest rate percent senior unsecured notes percent senior unsecured notes incorporates initial discount debt issuance fees percent percent respectively interest rate payable notes subject adjustment notes generally restrict scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted redemption date semiannual basis using rate treasury notes comparable remaining terms plus basis points notes basis points notes change control triggering event occurs defined prospectus holders notes right require scheringplough repurchase part notes cash payment equal percent aggregate principal amount notes repurchased plus accrued unpaid interest date purchase scheringplough used net proceeds issuance senior unsecured notes fund portion purchase price obs acquisition see note acquisition november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering billion interest notes payable semiannually subject rate adjustment follows rating assigned particular series notes either moodys investors service inc moodys standard poors rating services sp changes rating set forth interest rate payable series notes initial interest rate percent notes due percent notes due plus additional interest rate set forth moodys sp additional interest rate oodys rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade either moodys sp respectively notes subsequently rated baa moodys bbb sp upon issuance notes rated moodys sp july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december resulted percent interest rate payable notes due percent interest rate payable notes due increased december notes rated baa moodys sp table contents notes consolidated financial statements continued senior unsecured notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes term loan october scheringplough entered fiveyear senior unsecured eurodenominated term loan facility syndicate banks october scheringplough drew euro billion billion term loan fund portion purchase price obs acquisition see note acquisition additional information new term loan floating interest rate weighted average rate requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing term loan term loan also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets addition scheringploughs international subsidiaries approximately million available unused lines credit various financial institutions december aggregate amount maturities aggregate amount maturities longterm debt next five years thereafter follows th ereafte r dollars millions longterm debt credit facilities august scheringplough entered billion revolving credit agreement syndicate banks terminated billion credit facility mature may credit facility floating interest rate matures august requires scheringplough maintain net debt total capital ratio percent percent thereafter net debt equals total debt less cash cash equivalents shortterm investments marketable securities total capital equals sum total debt total shareholders equity excluding cumulative effect acquired inprocess research development connection acquisition consummated closing credit facility credit facility also generally restricts scheringplough creating assuming liens entering sale leaseback transactions unless aggregate outstanding indebtedness secured liens related sale leaseback transactions exceed percent consolidated net tangible assets credit line available general corporate purposes considered support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december borrowings outstanding facility scheringplough billion credit facility terminated august december million drawn facility whollyowned international subsidiary purposes table contents notes consolidated financial statements continued funding repatriations ajca borrowing amount fully repaid december borrowings outstanding facility addition credit facility scheringplough entered million credit facility fourth quarter purposes funding repatriations ajca december entire amount drawn whollyowned international subsidiary fund repatriations facility paid full terminated commitments total rent expense amounted million million million respectively future annual minimum rental commitments next five years noncancelable operating leases december follows million million million million million aggregate minimum lease obligations million due thereafter december scheringplough commitments totaling million million related capital expenditures made respectively financial instruments sfas requires derivatives recorded balance sheets fair value addition statement also requires effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized statements consolidated operations occur risks policy objectives scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes currently scheringplough deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments limited basis scheringplough hedge selective foreign currency risks derivatives scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide natural level protection adverse changes exchange rates furthermore risk adverse exchange rate change somewhat mitigated fact scheringploughs international operations widespread scheringploughs senior unsecured eurodenominated notes eurodenominated term loan designated effective economic hedges net investment foreign operation accordance sfas foreign currency translation foreign currency transaction gains losses eurodenominated debt instruments included foreign currency translation adjustment within comprehensive income part overall risk management strategy consideration various preliminary financing scenarios associated acquisition obs scheringplough purchased eurodenominated currency options mitigate exposure event significant strengthening euro compared us dollar scheringplough purchased options aggregate premiums approximately million received proceeds million upon termination options resulting net realized gain million derivatives qualify hedge accounting accordance sfas accordingly gain derivatives recognized statement consolidated operations derivatives shortterm trading nature hedge specific financing table contents notes consolidated financial statements continued investment transaction accordingly cash impacts derivatives classified operating cash flows statement consolidated cash flows see note incomeexpense net december open foreign currency option contracts scheringplough executed series interest rate swaps anticipation financing acquisition obs objective swaps hedge interest rate payments made future issuances debt swaps designated cash flow hedges future interest payments accordance sfas effective portion gains losses hedges reported comprehensive income ineffective portion reported operations connection eurodenominated debt issuances described note borrowings commitments portions swaps deemed ineffective scheringplough recognized million loss statement consolidated operations effective portion swaps million recorded comprehensive income recognized interest expense life related debt cash flows related interest rate swaps classified operating cash flows statement consolidated cash flows see note incomeexpense net december open interest rate swaps scheringplough mitigates credit risk derivative instruments dealing counterparties considered high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instruments manner generate trading profits scheringplough classifies cash flows derivatives accounted hedges category item hedged table presents carrying values estimated fair values certain scheringploughs financial instruments december estimated fair values determined based market prices available dealer quotes carrying values financial instruments including cash cash equivalents approximated estimated fair values december carrying estimated carrying estimated value fair value value fair value dollars millions assets shortterm investments longterm investments liabilities shortterm borrowings current portion longterm debt longterm debt longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held non qualified trusts fund longterm employee benefit obligations included liabilities consolidated balance sheets assets used fund related employee benefit obligations shareholders equity preferred shares december scheringplough authorized shares preferred stock consists preferred shares designated percent mandatory convertible preferred stock table contents notes consolidated financial statements continued preferred shares whose designations yet determined december shares percent mandatory convertible preferred stock issued outstanding mandatory convertible preferred stock august scheringplough issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale preferred stock fund portion purchase price obs acquisition see note acquisition additional information share preferred stock automatically convert common shares scheringplough depending average closing price scheringploughs common shares trading day period ending third trading day prior mandatory conversion date august defined prospectus preferred shareholders may elect convert time prior august minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price scheringploughs common shares exceeds least trading days within period consecutive trading days scheringplough may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares share preferred stock preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent scheringplough legally permitted pay dividends board directors declares dividend payable scheringplough pay dividends dividend payment date dividend payment dates february may august november year first dividend paid november mandatory convertible preferred stock year ended december shares percent mandatory convertible preferred stock issued august preferred stock converted shares scheringplough common stock following conversion shares preferred stock resumed status authorized unissued preferred stock undesignated series available future issuance equity issuance treasury shares august scheringplough issued common shares treasury shares per share net proceeds scheringplough approximately billion deducting commissions discounts underwriting expenses scheringplough used net proceeds sale common shares fund portion purchase price obs acquisition see note acquisition additional information summary treasury share transactions years ended december follows shares millions share balance january issuance common shares stock incentive plans activities share balance december included treasury share balance million shares acquired subsidiary scheringplough open market purchase program shares considered table contents notes consolidated financial statements continued treasury shares new jersey law however like treasury shares may voted considered outstanding shares determining necessary votes approve matter submitted stockholder vote subsidiary receive dividends shares effective september board directors scheringplough adopted amended restated certificate incorporation reflecting automatic conversion preferred stock issued shares common stock september terms preferred stock insurance coverage scheringplough maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly scheringplough selfinsures substantial proportion risk relates products liability availability commercial insurance become restrictive scheringplough continually assesses best way provide insurance needs segment information scheringplough three reportable segments human prescription pharmaceuticals animal health consumer health care segment sales lossprofit data follow consistent scheringploughs current management reporting structure human prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products animal health segment discovers develops manufactures markets animal health products consumer health care segment develops manufactures markets overthecounter foot care sun care products primarily us table contents notes consolidated financial statements continued net sales major product segment dollars millions human prescription pharmaceuticals remicade nasonex pegintron temodar clarinexaerius claritin rx avelox integrilin rebetol caelyx intron subutexsuboxone asmanex pharmaceutical animal health consumer health care otc foot care sun care consolidated net sales net sales geographic area dollars millions united states europe canada latin america pacific area asia consolidated net sales table contents notes consolidated financial statements continued scheringplough subsidiaries countries outside us net sales presented geographic area scheringploughs customers located following foreign countries accounted percent consolidated net sales past three years consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions total international net sales france japan canada italy net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions mckesson corporation cardinal health lossprofit segment year e nded ecem b er dollars millions human prescription pharmaceuticals animal health consumer health care corporate including net interest income million million million respectively consolidated lossprofit tax cumulative effect change accounting principle human prescription pharmaceuticals segments loss includes billion purchase accounting items including acquired inprocess research development billion animal health segments loss includes million purchase accounting items including acquired inprocess research development million scheringploughs net sales include sales vytorin zetia managed joint venture merck scheringplough accounts joint venture equity method accounting see note equity income additional information human prescription pharmaceuticals segment includes equity income merckscheringplough joint venture corporate includes interest income expense foreign exchange gains losses currency option gains headquarters expenses special charges miscellaneous items accounting policies table contents notes consolidated financial statements continued used segment reporting described note summary significant accounting policies corporate includes special acquisition related charges million comprised million integration related costs obs acquisition million severance charges part integration activities estimated charges relate reportable segments follows human prescription pharmaceuticals million animal health million corporate million corporate includes special charges million primarily related changes scheringploughs manufacturing operations us puerto rico announced june related human prescription pharmaceuticals segment included cost sales charges approximately million manufacturing streamlining actions primarily related human prescription pharmaceuticals segment corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve million representing scheringploughs current estimate resolve massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters estimated charges relate reportable segments follows human prescription pharmaceuticals million consumer health care million animal health million corporate million supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows mount pe rcentage dollars millions us nasonex otc claritin international remicade longlived assets geographic location dollars millions united states netherlands ireland singapore total longlived assets shown geographic location primarily intangibles property significant increase longlived assets december due obs acquisition scheringplough disaggregate assets segment basis internal management reporting therefore information presented table contents notes consolidated financial statements continued consent decree may scheringplough agreed fda entry consent decree resolve issues related compliance current good manufacturing practices cgmp certain scheringploughs facilities new jersey puerto rico consent decree decree summary decree required scheringplough make payments totaling million two equal installments million paid addition decree required scheringplough complete revalidation programs manufacturing processes used produce bulk active pharmaceutical ingredients finished drug products covered facilities well implement comprehensive cgmp work plan facility scheringplough completed requirements accordance schedules required decree obtained thirdparty certification completion work plan required decree august scheringplough announced dissolution consent decree us district court district new jersey legal environmental regulatory matters background scheringplough involved various claims investigations legal proceedings scheringplough records liability contingencies probable liability incurred amount reasonably estimated scheringplough adjusts liabilities contingencies reflect current best estimate probable loss minimum liability case may best estimate determinable scheringplough records minimum amount within probable range liability expected insurance recoveries considered determining amounts recorded liabilities environmental related matters scheringplough believes loss contingency reasonably possible rather probable amount loss estimated liability recorded however liability reasonably possible disclosure loss contingency made scheringplough reviews status claims investigations legal proceedings ongoing basis including related insurance coverages time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs consolidated results operations cash flows financial condition except matters discussed remainder note recorded liabilities contingencies december related expenses incurred year ended december material opinion management based advice legal counsel ultimate outcome matters except matters discussed remainder note material impact scheringploughs consolidated results operations cash flows financial condition enhance matter january merck scheringplough cholesterol joint venture announced primary endpoint results enhance effect combination ezetimibe highdose simvastatin vs simvastatin alone atherosclerotic process patients heterozygous familial hypercholesterolemia clinical trial scheringplough encountered challenge results enhance trial joint venture products zetia vytorin became subject much media scrutiny prior fuller discussions trial results appropriate medical forums discussion scheduled american college cardiology meeting march scheringplough joint venture andor joint venture partner merck co inc merck received several letters congress including house committee energy commerce house subcommittee oversight investigations ranking minority member senate finance table contents notes consolidated financial statements continued committee collectively seeking combination witness interviews documents information variety issues related merckscheringplough cholesterol joint ventures enhance clinical trial companies sale promotion vytorin well sales stock companies corporate officers since april several subpoenas state officials state attorney general state department justice several states including connecticut new york oregon seeking similar information documents scheringplough cooperating investigations working merck respond inquiries addition since midjanuary scheringplough become aware served litigation including civil class action lawsuits alleging common law state consumer fraud claims connection scheringploughs sale promotion merckscheringplough jointventure products vytorin zetia several putative shareholder securities class action lawsuits several officers also named defendants alleging false misleading statements omissions scheringplough representatives related timing disclosures concerning enhance results allegedly violation sections b securities exchange act shareholder derivative action alleging board directors breached fiduciary obligations relating timing release enhance results letter behalf single shareholder requesting board directors investigate allegations putative securities class actions warranted bring appropriate legal action behalf scheringplough scheringplough cooperating fully government investigations intends vigorously defend lawsuits filed related enhance study patent matters described patents trademarks intellectual property rights item business k intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect schering plough dr scholls freeze away july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product matter settled material impact scheringploughs financial statements stipulation dismissing action filed parties february awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies table contents notes consolidated financial statements continued securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege schering plough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks compensatory damages behalf class court certified shareholder class october notice pendency class action sent members class july discovery completed motions summary judgment briefed pending erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anti competitive effects settlements resolved scheringploughs favor alleged class action suits filed federal state courts behalf direct indirect purchasers kdur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages discovery ongoing thirdparty payor actions several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs table contents notes consolidated financial statements continued claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently tried newark district court scheringploughs tax reserves adequate cover abovementioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection settlement massachusetts investigation commencing new fiveyear term failure comply obligations cia could result financial penalties matters products liability beginning may number complaints filed various jurisdictions asserting claims organon usa inc organon pharmaceuticals usa inc andor organon international organon arising scheringploughs marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages heart attacks strokes majority cases currently pending united states district court district new jersey cases pending wisconsin missouri new york georgia french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating subutex one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies july juge des liberts et de la dtention ordered annulment search seizure procedural grounds july french authority appealed order french supreme court april competitor also requested interim relief portion granted french competition authority december interim relief required scheringploughs french subsidiary publish two specialized newspapers information including generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirmed decision french competition authority environmental scheringplough responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law scheringplough alleged potentially responsible party prp scheringplough believes remote time material liability relation sites scheringplough estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps scheringplough records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries company december related statements consolidated operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements effective january company adopted statement financial accounting standards sfas revised sharebased payment discussed note consolidated financial statements effective december company adopted sfas employers accounting defined benefit pension postretirement plans discussed note consolidated financial statements effective january company adopted financial accounting standards board interpretation accounting uncertainty income taxes also audited accordance standards public company accounting oversight board united states companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries quarterly data unaudited three nths ended march june september december dollars millions except per share figures net sales cost sales gross margin selling general administrative research development acquired inprocess research development incomeexpense net special charges acquisitionrelated charges equity income cholesterol joint venture incomeloss income taxes income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss dividends preferred shares net incomeloss available common shareholders diluted earningsloss per common share earningsloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax diluted earnings per common share basic earningsloss per common share earningsloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax basic earningsloss per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions table contents operating results three month period ended december reflects closing obs acquisition november including impacts purchase accounting accordance sfas business combinations net sales third quarter included favorable impact approximately million resulting reversal previously accrued rebate amounts tricare retail pharmacy program us federal court appeals ruled pharmaceutical manufacturers obligated pay diluted earnings per common share three month period ended september calculated using numerator million arithmetic sum net income available common shareholders million plus dividends million related preferred stock dilutive denominator represents average diluted shares outstanding third quarter see note special acquisition related charges manufacturing changes consolidated financial statements additional information relating special acquisitionrelated charges charges scheringploughs announced manufacturing changes scheringploughs approximate number holders record common shares january item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated scheringploughs disclosure controls procedures end period covered k concluded scheringploughs disclosure controls procedures effective also concluded changes scheringploughs internal control financial reporting occurred scheringploughs recent fiscal quarter materially affected reasonably likely materially affect scheringploughs internal control financial reporting part changing business environment scheringplough operates scheringplough replacing upgrading number information systems process ongoing several years connection changes part scheringploughs management internal control financial reporting disclosure controls procedures management concluded new systems least effective respect controls prior systems managements report internal control financial reporting management scheringplough corporation responsible establishing maintaining adequate internal control financial reporting scheringploughs internal control system designed provide reasonable assurance scheringploughs management board directors regarding preparation fair presentation published financial statements internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation presentation table contents scheringploughs management assessed effectiveness scheringploughs internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework managements assessment conclusion effectiveness internal control financial reporting december include review business process controls obs nv management assess internal control financial reporting obs nv acquisition occurred november within one year prior date consolidated financial statements allowable securities exchange commission guidelines obs nv represented approximately consolidated total assets december approximately consolidated revenues year ended december based assessment management believes december scheringploughs internal control financial reporting effective scheringploughs independent registered public accounting firm deloitte touche llp issued attestation report effectiveness scheringploughs internal control financial reporting report follows table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited internal control financial reporting scheringplough corporation subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission described managements report internal control financial reporting management excluded assessment internal control financial reporting organon biosciences nv acquired november whose financial statements constitute total assets total revenues consolidated financial statement amounts year ended december accordingly audit include internal control financial reporting organon biosciences nv companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission table contents also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february expressed unqualified opinion financial statements financial statement schedule included explanatory paragraph regarding companys adoption statement financial accounting standards sfas revised sharebased payment sfas employers accounting defined benefit pension postretirement plans financial accounting standards board interpretation accounting uncertainty income taxes deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant information concerning directors nominees directors incorporated reference proposal one elect thirteen directors oneyear term scheringploughs proxy statement annual meeting shareholders may information concerning executive officers included part filing caption executive officers registrant information concerning compliance section exchange act incorporated reference section beneficial ownership reporting compliance scheringploughs proxy statement annual meeting shareholders may information concerning audit committee audit committee financial expert incorporated reference information audit committee board directors practices audit committee report scheringploughs proxy statement annual meeting shareholders may scheringplough adopted code business conduct ethics standards global business practices applicable employees including chief executive officer chief financial officer controller scheringploughs standards global business practices available investor relations section scheringploughs website wwwscheringploughcom addition written copy materials provided charge writing office corporate secretary scheringplough corporation galloping hill road mail stop k kenilworth new jersey scheringplough intends satisfy disclosure requirement item form k regarding amendment waiver provision standards global business practices posting information website address specified item executive compensation information concerning executive compensation incorporated reference executive compensation scheringploughs proxy statement annual meeting shareholders may item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management incorporated reference stock ownership scheringploughs proxy statement annual meeting shareholders may table contents equity compensation plan information following information relates plans equity securities scheringplough may issued employees directors scheringplough plans equity securities may issued nonemployees except stock incentive plan certain stock options may transferable family members employeeoptionee related trusts column column c number securities number securities issued column b remaining available upon exercise weightedaverage future issuance outstanding exercise price equity compensation options warrants outstanding options plans excluding securities plan category rights warrants rights reflected column equity compensation plans approved security holders stock incentive plan na stock incentive plan stock incentive plan stock incentive plan directors compensation plan na na equity compensation plans approved security holders scheringplough ireland approved profit sharing scheme na na organon ireland limited employee share participation scheme na na intervet ireland limited employee share participation scheme na na total plans permit eligible employees work certain scheringplough irish subsidiaries enjoy tax advantages annual bonus amount varying percent percent pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts euro may deferred year employee employees may sell withdraw shares allocated accounts two three years item certain relationships related transactions information concerning certain relationships related transactions incorporated reference certain transactions procedures related party transactions director independence assessments scheringploughs proxy statement annual meeting shareholders may information concerning director independence incorporated reference director independence scheringploughs proxy statement annual meeting shareholders may item principal accountant fees services information concerning principal accountant fees services incorporated reference proposal two ratify designation deloitte touche llp audit scheringploughs books accounts scheringploughs proxy statement annual meeting shareholders may table contents part iv item exhibits financial statement schedules following documents filed part report financial statements financial statements set forth item k financial statement schedules table contents merckscheringplough cholesterol partnership combined financial statements index p age combined statements net sales contractual expenses years ended december combined balance sheets december combined statements cash flows years ended december combined statements partners capital years ended december notes combined financial statements years ended december independent auditors report schedule ii valuation qualifying accounts schedules listed omitted applicable required table contents index exhibits unless otherwise indicated exhibits part commission file number exhibit number description location amended restated certificate incorporation incorporated reference exhibit scheringploughs k filed september b amended restated bylaws incorporated reference exhibit scheringploughs k filed june rights agreement scheringplough incorporated reference exhibit bank new york dated june scheringploughs filed june b form participation rights agreement incorporated reference exhibit scheringplough chase manhattan bank scheringploughs registration statement form national association trustee amendment filed december file ci indenture dated november incorporated reference exhibit scheringplough bank new york trustee scheringploughs k filed november cii first supplemental indenture including form note incorporated reference exhibit dated november scheringploughs k filed november ciii second supplemental indenture including form note incorporated reference exhibit dated november scheringploughs k filed november civ global senior note due incorporated reference exhibit civ scheringploughs k year ended december cv global senior note due incorporated reference exhibit cv scheringploughs k year ended december cvi third supplemental indenture including form note incorporated reference exhibit dated september scheringploughs k filed september cvii fourth supplemental indenture including form note incorporated reference exhibit dated october scheringploughs k filed october directors compensation plan amended restated incorporated reference exhibit hiii effective june amendments scheringploughs q period ended september september bi stock incentive plan incorporated reference exhibit scheringploughs q period ended september bii amendment stock incentive plan effective incorporated reference exhibit february scheringploughs q period ended march biii amendment stock incentive plan effective incorporated reference exhibit c february scheringploughs k year ended december c stock incentive plan amended february incorporated reference exhibit scheringploughs k year ended december table contents exhibit number description location stock incentive plan amended restated attached effective february ei letter agreement dated november incorporated reference exhibit eiii robert bertolini scheringplough scheringploughs k year ended december eii employment agreement effective upon change incorporated reference exhibit control dated december robert scheringploughs k filed december bertolini scheringplough corporation eiii employment agreement dated may incorporated reference exhibit carrie cox scheringplough scheringploughs k filed may eiv employment agreement dated april incorporated reference exhibit fred hassan scheringplough scheringploughs k filed april ev employment agreement dated december incorporated reference exhibit ev thomas p koestler phd scheringploughs k year ended december scheringplough evi letter agreement dated march incorporated reference exhibit thomas j sabatino jr scheringplough scheringploughs q period ended march evii employment agreement effective upon change incorporated reference exhibit ev control dated april thomas j scheringploughs k year ended december sabatino jr scheringplough eviii employment agreement dated december attached brent saunders scheringplough eix form employment agreement effective upon change incorporated reference exhibit ev control scheringplough certain scheringploughs k year ended december executives new agreements beginning december f operations management team incentive plan incorporated reference exhibit mii amended restated effective june scheringploughs q period ended september g cash longterm incentive plan amended incorporated reference exhibit n restated effective january scheringploughs k year ended december h longterm performance share unit incentive plan incorporated reference exhibit amended restated effective january scheringploughs k year ended december transformational performance contingent shares incorporated reference exhibit p program scheringploughs k year ended december j severance benefit plan amended restated attached effective january k savings advantage plan amended restated incorporated reference exhibit exiii effective january scheringploughs q period ended september table contents exhibit number description location l supplemental executive retirement plan amended incorporated reference exhibit ev restated january scheringploughs k year ended december retirement benefits equalization plan amended incorporated reference exhibit l restated january scheringploughs k year ended december n executive incentive plan amended restated incorporated reference exhibit ai october scheringploughs k year ended december deferred compensation plan amended restated incorporated reference exhibit october scheringploughs k year ended december p amended restated defined contribution trust incorporated reference exhibit aii scheringploughs k year ended december q amended restated serp rabbi trust agreement incorporated reference exhibit g scheringploughs k year ended december r cholesterol governance agreement dated may incorporated reference exhibit among scheringplough merck co inc scheringploughs k dated october parties signatory thereto first amendment cholesterol governance incorporated reference exhibit agreement dated december among scheringploughs k filed october scheringplough merck co inc parties signatory thereto master agreement dated december incorporated reference exhibit among scheringplough merck co inc scheringploughs k filed october parties signatory thereto u letter agreement dated april relating consent incorporated reference exhibit decree scheringploughs q period ended march v distribution agreement scheringplough incorporated reference exhibit u schering centocor inc dated april ploughs amended k year ended december filed may w amendment agreement distribution agreement incorporated reference exhibit centocor inc development llc scheringploughs k filed december scheringplough ireland company x share purchase agreement akzo nobel nv incorporated reference exhibit scheringplough international cv scheringplough scheringploughs k filed october corporation computation ratio earnings fixed charges attached standards global business practices covers incorporated reference exhibit employees including senior financial officers scheringploughs k filed september subsidiaries registrant attached table contents e xhib number description location consent independent registered public accounting attached firm independent auditors consent attached power attorney attached sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer sarbanesoxley act section certification attached chairman board chief executive officer sarbanesoxley act section certification attached executive vice president chief financial officer compensatory plan contract arrangement certain portions exhibit omitted pursuant request confidential treatment nonpublic information filed separately securities exchange commission pursuant rule b securities exchange act amended copies